Cyalume Technologies (CYLU) 10-K 7 Apr 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 30, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	Cyalume Technologies Holdings, Inc.
Entity Central Index Key	1,335,293
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 629,442
Trading Symbol	CYLU
Entity Common Stock, Shares Outstanding		21,400,244

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash		$ 1,526	$ 2,358
Accounts receivable, net of allowance for doubtful accounts of $5 and $22, respectively		4,299	3,622
Inventories, net		7,528	7,826
Income taxes refundable		442	0
Debt issue costs, current		809	21
Prepaid expenses and other current assets		797	627
Total current assets		15,401	14,454
Property, plant and equipment, net		6,795	7,120
Goodwill	[1]	7,992	7,992
Other intangible assets, net		5,691	6,591
Debt issue costs, noncurrent		809	5
Other noncurrent assets		0	13
Total assets		36,688	36,175
Current liabilities:
Line of credit		1,000	2,050
Current portion of notes payable		492	5,775
Accounts payable		947	2,144
Accrued expenses		3,858	2,690
Deferred revenue and deferred rent		125	181
Income taxes payable		327	644
Current portion of capital lease obligation		0	7
Warrants liability		54	25
Total current liabilities		6,803	13,516
Notes payable, net of current portion		16,016	10,214
Note payable due to related parties		0	2,100
Deferred income taxes		567	430
Asset retirement obligation		214	204
Legal obligation, noncurrent		0	2,781
Other noncurrent liabilities, net of current portion		81	78
Total liabilities		$ 23,681	$ 29,323
Commitments and contingencies (Note 16)
Stockholders' equity:
Series B convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 1,000 shares issued and outstanding		$ 1,401	$ 1,401
Common stock, $0.001 par value; 150,000,000 shares authorized; 21,400,244 shares issued and outstanding		21	21
Additional paid-in capital		102,624	103,014
Accumulated deficit		(100,315)	(103,590)
Accumulated other comprehensive loss		(979)	(661)
Total stockholders’ equity		2,752	185
Total liabilities and stockholders' equity		36,688	36,175
Series C Preferred Stock [Member]
Temporary Equity
Temporary Equity		2,367	2,103
Series D Convertible Preferred Stock [Member]
Temporary Equity
Temporary Equity		2,751	0
Series A Convertible Preferred Stock [Member]
Temporary Equity
Temporary Equity		$ 5,137	$ 4,564
[1]	Gross amount of goodwill was approximately $67.7 million as of December 31, 2015 and 2014. Accumulated impairment losses incurred prior to 2015 were approximately $59.7 million as of December 31, 2015 and 2014.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts receivable, allowance for doubtful accounts	$ 5	$ 22
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	21,400,244	21,400,244
Common stock, shares outstanding	21,400,244	21,400,244
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	123,097	123,077
Preferred stock, shares outstanding	123,097	123,077
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000
Series B convertible preferred stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	10	10
Preferred stock, shares outstanding	10	10

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues	$ 37,842	$ 33,322
Cost of revenues	20,448	19,392
Gross profit	17,394	13,930
Other expenses (income):
Sales and marketing	2,375	3,395
General and administrative	7,576	5,662
Research and development	1,396	1,506
Interest expense, net	2,934	2,086
Interest expense - related party	100	356
Amortization of intangible assets	954	1,812
Impairment loss on intangible assets	0	9,580
Legal settlement	(1,381)	0
Change in fair value of warrants liability	29	(4,852)
Loss on extinguishment of debt - related party	0	527
Other expenses (income), net	(73)	336
Total other expenses	13,910	20,408
Income (loss) before income taxes	3,484	(6,478)
Provision for income taxes	209	1,238
Net income (loss)	3,275	(7,716)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(318)	(443)
Other comprehensive loss	(318)	(443)
Comprehensive income (loss)	2,957	(8,159)
Net income (loss)	3,275	(7,716)
Net income (loss) available to common stockholders - basic	2,438	(13,249)
Convertible related party promissory note	45	0
Series A convertible preferred stock dividends	573	0
Net income (loss) available to common stockholders - diluted	$ 3,056	$ (13,249)
Earnings (loss) per common share:
Basic (in dollars per share)	$ 0.11	$ (0.62)
Diluted (in dollars per share)	$ 0.03	$ (0.62)
Weighted average outstanding common shares used to compute earnings (loss) per common share:
Basic (in shares)	21,400,244	21,294,432
Diluted (in shares)	102,376,045	21,294,432
Series A Convertible Preferred Stock [Member]
Other comprehensive income (loss), net of tax:
Preferred stock dividends	$ (573)	$ (509)
Series C Preferred Stock [Member]
Other expenses (income):
Net income (loss)	0	0
Other comprehensive income (loss), net of tax:
Other comprehensive loss	0	0
Net income (loss)	0	0
Preferred stock dividends	(264)	(103)
Series A Deemed Dividend [Member]
Other comprehensive income (loss), net of tax:
Preferred stock dividends	0	(2,422)
Series B Deemed Dividend [Member]
Other comprehensive income (loss), net of tax:
Preferred stock dividends	0	(1,098)
Series C Deemed Dividend [Member]
Other comprehensive income (loss), net of tax:
Preferred stock dividends	$ 0	$ (1,401)

Consolidated Statements of Chan

Consolidated Statements of Changes in Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Contingent Consideration Classified as Equity [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]Contingent Consideration Classified as Equity [Member]	Series C Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]Contingent Consideration Classified as Equity [Member]	Common Stock [Member]	Common Stock [Member]Contingent Consideration Classified as Equity [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Contingent Consideration Classified as Equity [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Contingent Consideration Classified as Equity [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Other Comprehensive Loss [Member]Contingent Consideration Classified as Equity [Member]
Balance at Dec. 31, 2013	$ 6,504		$ 4,055		$ 0	$ 0	$ 0		$ 21		$ 102,575		$ (95,874)		$ (218)
Balance (in shares) at Dec. 31, 2013			123,077						20,738,260
Proceeds received from issuance of Series C preferred stock	0		$ 0		$ 1,000	0	0		$ 0		0		0		0
Proceeds received from issuance of Series C preferred stock (in shares)					1,000
Proceeds received from issuance of Series B convertible preferred stock	1,000		0		$ 0	0	$ 1,000		0		0		0		0
Proceeds received from issuance of Series B convertible preferred stock (in shares)							1,000
Series A, B and C allocation of fair value	401		0		(401)	0	$ 401		0		0		0		0
Series A, B and C preferred stock issuance costs	(321)		0		0	0	0		0		(321)		0		0
Dividends accrued on Series A and Series C preferred stock	(612)		509		103	0	0		0		(612)		0		0
Reversal of forfeited restricted awards	0		0		0	0	0		$ 0		0		0		0
Reversal of forfeited restricted awards (in shares)									(3,333)
Granite Patriot Warrants amended in connection with debt refinancing	(72)		0		0	0	0		$ 0		(72)		0		0
Common stock issuance - payment of contingent consideration liability		$ 241		$ 0	0	0		$ 0		$ 0		$ 241		$ 0		$ 0
Common stock issuance - payment of contingent consideration liability (in shares)										350,000
Common stock issuance - issuance of shares to Selway for services provided	157		$ 0		$ 0	0	$ 0		$ 0		157		0		0
Common stock issuance - issuance of shares to Selway for services provided (in shares)									242,308
Balance (in shares) at Dec. 31, 2014			123,077		1,000		1,000		21,400,244
Shares issued - warrant exercise and adjustment to warrant liability	45		$ 0		$ 0	0	$ 0		$ 0		45		0		0
Shares issued - warrant exercise and adjustment to warrant liability (in shares)									73,009
Excess of Amended JFC Note Fair Value over Face Value of $2.1M	483		0		0	0	0		$ 0		483		0		0
Termination of USVC common and preferred warrants	1,525		0		0	0	0		0		1,525		0		0
Series C deemed dividends	(1,401)		0		1,401	0	0		0		(1,401)		0		0
Share-based compensation	394		0		0	0	0		0		394		0		0
Net income / loss	(7,716)		0		0	0	0		0		0		(7,716)		0
Other comprehensive loss	(443)		0		0	0	0		0		0		0		(443)
Balance at Dec. 31, 2014	185		4,564		2,103	0	1,401		21		103,014		(103,590)		(661)
Dividends accrued on Series A and Series C preferred stock	(837)		573		264	0	0		0		(837)		0		0
Issuance of Series A and Series D convertible preferred stock	0		$ 0		$ 0	$ 2,751	$ 0		$ 0		0		0		0
Issuance of Series A and Series D convertible preferred stock (in shares)			20			10
Balance (in shares) at Dec. 31, 2015			123,097		1,000	10	1,000		21,400,244
Effect of modification of warrant terms	43		$ 0		$ 0	$ 0	$ 0		$ 0		43
Share-based compensation	404		0		0	0	0		0		404		0		0
Net income / loss	3,275		0		0	0	0		0		0		3,275		0
Other comprehensive loss	(318)		0		0	0	0		0		0		0		(318)
Balance at Dec. 31, 2015	$ 2,752		$ 5,137		$ 2,367	$ 2,751	$ 1,401		$ 21		$ 102,624		$ (100,315)		$ (979)

Preferred Stock and Equity Stat

Preferred Stock and Equity Statements (Parenthetical) $ in Millions	Dec. 31, 2014USD ($)
Unsecured Debt	$ 2.1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ 3,275	$ (7,716)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment	1,228	1,367
Amortization of intangible assets, debt issuance costs and debt discount	1,855	2,050
Provision for deferred income taxes	138	430
Share-based compensation expense	404	394
Impairment loss on intangible assets	0	9,580
Change in fair value of derivatives	(29)	0
Change in fair value of warrants liability	29	(4,852)
Non-cash interest expense	414	1,017
Legal settlement	(1,381)	0
Loss on extinguishment of debt - related party	0	527
Other non-cash expenses	18	69
Changes in operating assets and liabilities:
Accounts receivable	(154)	112
Inventories	203	2,818
Prepaid expenses and other current assets	23	157
Restricted cash	(153)	0
Accounts payable and accrued liabilities	(21)	(3,347)
Accrued interest on note payable to related party	(504)	252
Deferred revenue and deferred rent	(56)	101
Income taxes payable	(743)	723
Change in legal obligation - settlement payments	(1,400)	(1,250)
Net cash provided by operating activities	3,146	2,432
Cash flows from investing activities:
Purchases of long-lived assets	(1,034)	(664)
Payments for intangibles	(157)	(172)
Net cash used in investing activities	(1,191)	(836)
Cash flows from financing activities:
(Repayments on) proceeds from TD Bank line of credit, net	(2,050)	450
Principal repayments on CTI long term notes payable	(15,880)	(1,912)
Borrowings on Monroe line of credit, net	1,000	0
Borrowings on Monroe long term notes payable, net of repayments	18,619	0
Repayment of related party note payable	(2,100)	0
Principal payments on capital lease obligations	(7)	(15)
Proceeds received from issuance of Series C and Series B preferred stock	0	2,000
Proceeds received from warrant exercise	0	1
Payment of preferred stock issuance costs	0	(321)
Repayment of legal settlement promissory note	(215)	(215)
Payment of debt issuance and deferred financing costs	(2,118)	(21)
Net cash used in financing activities	(2,751)	(33)
Effect of exchange rate changes on cash	(36)	(70)
Net increase (decrease) in cash	(832)	1,493
Cash, beginning of period	2,358	865
Cash, end of period	$ 1,526	$ 2,358

BACKGROUND AND DESCRIPTION OF B

BACKGROUND AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
BACKGROUND AND DESCRIPTION OF BUSINESS	1. BACKGROUND AND DESCRIPTION OF BUSINESS These consolidated financial statements and footnotes include the financial position and operations of Cyalume Technologies Holdings, Inc. (“Cyalume” or the “Company”), a holding company that is the sole shareholder of Cyalume Technologies, Inc. (“CTI”), of Cyalume Specialty Products, Inc. (“CSP”) and of CT SAS Holdings, Inc. (“CT SAS Holdings”). CTI is the sole shareholder of Cyalume Realty, Inc. (“CRI”) and Combat Training Solutions, Inc. (“CTS”) and CT SAS Holdings is the sole shareholder of Cyalume Technologies, SAS (“CTSAS”). All significant intercompany accounts and transactions have been eliminated in consolidation. The Company’s primary focus is providing tactical and training solutions to the military of the U.S. and other countries through both products and services. CTI and CTSAS manufacture and sell chemiluminescent products and reflective and photoluminescent materials to military, ammunition, commercial and public safety markets. CTSAS is located in France and represents us in certain international markets, primarily Europe and the Middle East. CTI sells to customers in all other geographic markets. CTI’s and CTSAS’ business operations constitute the majority, based on revenues and assets, of our consolidated business operations. CSP manufactures and sells specialty chemical products to the defense, pharmaceutical, cosmetic and other markets. CSP’s operations are located in Bound Brook, New Jersey. CRI previously owned land located in Colorado Springs, Colorado. The land was transferred in connection with a 2013 legal settlement and therefore, this subsidiary no longer has any activity. CTS provides its customers with battlefield effects simulation products while its services include planning and implementing tactical training exercises simulating real-world experiences. These products allow military and law enforcement professionals to maintain operational readiness through safe, live training and hands-on situational exercises. The Company’s business is managed and financial results are reported as one segment. The CEO, who is the chief operating decision maker, focuses on consolidated results to make strategic and tactical decisions. The Company’s one operating segment consists of three reporting units: Chemical Light (the operations of CTI, CTS and CTSAS), Specialty Products (the operations of CSP) and Other (the operations of CRI, the holding company CT SAS Holdings and the parent company Cyalume Technologies Holdings, Inc.).

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES The accounting records of our France-based subsidiary CTSAS are maintained in Euros, their local and functional currency. For consolidation, revenue and expense transactions are translated to U.S. dollars using the average exchange rate of the month in which the transaction took place. Assets and liabilities are translated to U.S. dollars using the exchange rate in effect as of the balance sheet date. Equity transactions are translated to U.S. dollars using the exchange rate in effect as of the date of the equity transaction. Translation gains and losses are reported as a component of accumulated other comprehensive income (loss) within stockholders’ equity. Gains and losses resulting from transactions which are denominated in other than the functional currency are reported as other income or loss in the statement of comprehensive income (loss) in the period the gain or loss occurred. Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to the Company’s historical classification of legal settlement payments from financing activities to operating activities in the statement of cash flows. Historically, the Company classified cash flows associated with obligations relating to the Omniglow Settlement Agreement as cash flows from financing activities based on the presence of financing elements in the Omniglow Settlement Agreement. However as these obligations also possess elements of operating activities, the Company has determined that it will classify the related cash flows as cash flows from operating activities. Accordingly, prior period amounts were reclassified in the Consolidated Statements of Cash Flows to conform to the current year presentation. See Note 16 – Commitments and Contingencies for additional information pertaining to these legal settlement payments. Comprehensive Income (Loss) Comprehensive income (loss) accounts for changes in stockholders’ equity resulting from non-stockholder sources. All transactions that would cause comprehensive income (loss) to differ from net income (loss) have been recorded and disclosed and relate to the translation of the accounting records of our France-based subsidiary CTSAS. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are used when accounting for certain items such as reserves for inventory, accounts receivable and deferred tax assets; assessing the carrying value of intangible assets including goodwill; determining the useful lives of property, plant and equipment and intangible assets; determining asset retirement obligations ; and estimating parameters and assumptions used to determine the fair values of warrants and preferred stock Accounts receivable are recorded at the aggregate unpaid amount less any allowance for doubtful accounts. The allowance is based on historical bad debt experience and the specific identification of accounts deemed uncollectible. An account receivable’s delinquency status is determined based on its contractual terms. Interest is not charged on outstanding balances. Accounts are written off only when all methods of recovery have been exhausted. Credit risk is controlled through initial credit evaluations and approvals, credit limits, and monitoring procedures. Ongoing credit evaluations of customers are performed but do not require collateral to secure accounts receivable. Inventories are stated at the lower of cost (on a first-in first-out (“FIFO”) method) or net realizable value. The cost of inventory consists of raw material content, labor costs to produce the inventory and overhead costs incurred during production of the inventory. The Company periodically reviews the realizability of inventory. Provisions are recorded for potential obsolescence which requires management’s judgment. Conditions impacting the realizability of inventory could cause actual write-offs to be materially different than provisions for obsolescence. Property, plant and equipment are stated at cost. Depreciation is computed under the straight-line method over the estimated useful lives of four to eight years for equipment and 30 Property, plant and equipment assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Such reviews are based on a comparison of the asset’s undiscounted cash flows to the recorded carrying value for the asset. Impairment charges, if any, are recorded in the period in which the impairment is determined. Goodwill is deemed to have an indefinite life and accordingly, is not subject to amortization. Goodwill is subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon its estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined. The Company performs a traditional two-step process for assessing goodwill for impairment annually. The first step of the two-step process requires a comparison of estimated fair value for each reporting unit versus the carrying or book value. If the carrying value exceeds fair value, further analysis (step 2 of the two-step process) is required to determine the amount, if any, that goodwill is impaired. Fair value is determined using a discounted cash flow analysis. Intangible assets include developed technologies and patents, customer relationships, non-compete agreements, trademarks and trade names, all of which are amortized over their estimated useful lives. The carrying amounts of amortizing intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Costs incurred to register new patents or defend existing patents are capitalized, while costs to renew or extend the term of intangible assets are expensed when incurred. Costs incurred with third parties that are related to internally developing or successfully defending an intangible asset are capitalized as part of the intangible asset developed or defended and amortized over that asset’s remaining useful life. Such costs with third parties related to patent or trademark applications that are ultimately rejected by the relevant government authority are expensed upon rejection. Useful lives Patents and developed technologies (1) Purchased customer relationships 9 – 13 years Trademarks and trade names (2) Non-compete agreements 5 years (1) Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 5.3 (2) Trademarks and trade names of CTI are deemed to have a useful life of 15 4.3 Costs paid to lenders to obtain financing are presented as discounts on the related debt and are amortized to interest expense over the term of the related financing, using the effective interest method (unless the financing is a line of credit, in which case the straight-line method is used). Such costs paid to third parties are presented as assets and are amortized to interest expense in the same manner as costs paid to lenders. Derivatives are recorded at their fair value as of the balance sheet date. If a derivative qualifies for “hedge accounting” under U.S. GAAP and has been designated as a hedge by us, then the “effectively hedged” portion is recorded, as defined by U.S. GAAP, of changes in such derivatives’ fair value in accumulated other comprehensive loss, which is a component of our stockholders’ equity. The Company records (i) ineffectively hedged portions of such changes in fair value or (ii) changes in the fair value of derivatives not designated as a hedge in our consolidated statement of comprehensive loss in the period the change occurred. On the consolidated statement of cash flows, cash flows from derivative instruments accounted for as cash flow hedges are classified in the same category as the cash flows from the items being hedged. The Company uses fair values as determined by significant unobservable inputs. These estimated values are significant inputs into the Monte Carlo simulation method and the Black Scholes pricing model used to calculate the estimated fair value of common warrants and preferred warrants potentially settleable in cash, which are recorded as warrants liability. The estimated fair value of the common warrants and the preferred warrants are determined at each balance sheet date and the change in the estimated fair value of the warrants is reflected within the Company’s statements of comprehensive income (loss). Certain common and preferred warrants were terminated on July 30, 2014. Revenue from the sale of products or the providing of services is recognized when the earnings process is complete, the amount of recognizable revenue can be determined, the risks and rewards of ownership have transferred to the customer and collectability is reasonably assured. Depending on the terms of the individual sales arrangement with our customer, product sales are recognized at either the shipping point or upon receipt by the customer. Costs and related expenses to manufacture the products are recorded as costs of goods sold when the related revenue is recognized. Additionally, if the right of return is granted to the buyer in a product sale, revenue is deferred until enough historical customer data is available to reasonably estimate returns and related costs. Certain contracts provide for the sale of indefinite quantities of products at fixed per unit prices, subject to adjustment for certain economic factors. Revenue under these contracts is recognized when products ordered under the contracts are received by the customer. Whenever costs change, the pricing under these contracts is reviewed to determine whether they require the sale of products at a loss. To date, there are no loss contracts which would require the accrual of future losses in the current financial statements. Research and development services are provided for customers for which the Company earns payments that are contingent upon achieving a specific result (“milestones”). Upon achieving such milestones, revenue is recognized provided that the payment is (i) related to past performance, (ii) reasonable relative to all of the deliverables and payment terms within the arrangement with our customer, and (iii) nonrefundable. Sales taxes collected from customers are not considered revenue and are included in accounts payable and accrued expenses until remitted to the taxing authorities. Outbound shipping and handling costs are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). These costs were approximately $ 231,000 358,000 Advertising costs are expensed as incurred and are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). Advertising expense was approximately $ 67,000 151,000 Stock-based compensation is incurred related to awards of common stock, restricted common stock and options to employees and non-employees. Those awards granted to employees are measured at their fair value on the date the award is granted and are recognized in our consolidated financial statements over the period the grantee is required to provide services in exchange for the award. When recognized as an expense, the fair value of the award, less estimated forfeitures, is recognized on a straight-line basis over the award service period; if there is no such service period, then the entire fair value of the award is recognized as expense on the grant date. The fair value of share-based payments to non-employees is estimated at each reporting period, until a measurement date is reached, and recorded as expense over the service period. The Company has research and development groups with full-time chemists and engineers at both the West Springfield and Bound Brook facilities. The research and development groups are focused on maintaining quality of existing products, developing improvements to existing products, and developing new technologies and products with viable commercial applications. Research and development costs are expensed as incurred. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are recognized when, based upon available evidence, realization of the assets is more likely than not. In assessing the realization of long-term deferred income tax assets, it is considered whether it is more likely than not that the deferred income tax assets will be realized. The realization of deferred income tax assets depends upon future taxable income in years before net operating loss carryforwards expire. The recoverability of deferred income tax assets is evaluated on a quarterly basis. If the Company determines that it is more likely than not that deferred income tax assets will not be recovered, a valuation allowance is established against some or all deferred income tax assets. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceeds the amount measured as described above, if such a position existed, would be reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. There were no such positions as of December 31, 2015 or 2014. Interest on tax deficiencies is classified as interest expense and income tax penalties are classified as other expense. In September 2015, the IRS completed an audit of our tax return for the year 2013. There were no adjustments to our 2013 tax return. Our tax return filed for the year 2014 is still open for audit. The tax return for 2014 was filed on September 14, 2015 under a filing extension. The tax return for 2015 is expected to be filed under a filing extension prior to September 15, 2016. Basic earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the basic weighted average number of common shares outstanding. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. (in thousands, except shares and per share information) Year Ended December 31, 2015 2014 Numerator (in thousands): Net income (loss) $ 3,275 $ (7,716) Series A convertible preferred stock dividends (573) (509) Series C preferred stock dividends (264) (103) Series A deemed dividend 0 (2,422) Series B deemed dividend 0 (1,098) Series C deemed dividend 0 (1,401) Net income (loss) available to common stockholders – basic $ 2,438 $ (13,249) Effect of dilutive securities: Add: Convertible related party promissory note 45 0 Add: Series A convertible preferred stock dividends 573 0 Income (loss) available to common stockholders – diluted $ 3,056 $ (13,249) Denominator: Weighted average common shares outstanding – basic 21,400,244 21,294,432 Weighted average effect of dilutive common equivalent shares: Assumed conversion of Series A convertible preferred stock 37,598,865 0 Assumed conversion of Series B convertible preferred stock 35,713,147 0 Assumed conversion of Series D convertible preferred stock 4,661,221 0 Convertible related party note 2,766,876 0 Warrants 234,214 0 Options 1,478 0 Weighted average common shares outstanding – diluted 102,376,045 21,294,432 Earnings (loss) per common share: Basic $ 0.11 $ (0.62) Diluted $ 0.03 $ (0.62) Year Ended December 31, 2015 2014 Options 10,505,322 10,347,322 Series A convertible preferred stock 0 33,401,765 Series B convertible preferred stock 0 35,713,147 Amended related party note 0 3,997,074 Convertible notes payable 0 2,666,667 Warrants 455,514 455,514 A preferred warrant convertible into 123,077 123,077 6,153,850 6,153,850 In connection with the issuance of the Company's Series A preferred stock, warrants to purchase a total of 528,523 174,404 174,404 Under U.S. GAAP, the Company is required to record certain financial assets and liabilities at fair value and may choose to record other financial assets and financial liabilities at fair value as well. Also under U.S. GAAP, the Company is required to record nonfinancial assets and liabilities at fair value due to events that may or may not recur in the future, such as an impairment event. When required to record such assets and liabilities at fair value, that fair value is estimated using an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. That fair value is determined based on significant inputs contained in a fair value hierarchy as follows: Level 1 Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three general valuation techniques that may be used to measure fair value, as described below: Market Approach Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources. Cost Approach Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Income Approach Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate. The following are recent accounting pronouncements that have affected our consolidated financial statements or may affect them in the future. In May 2014, the Financial Accounting Standards Board (“ Accounting Standards Update (“ Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30) Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740) as of December 31, 2015 on a prospective basis. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our December 31, 2015 consolidated balance sheet. Prior balance sheets were not retrospectively adjusted In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) statements.

IMPAIRMENT CHARGES

IMPAIRMENT CHARGES	12 Months Ended
	Dec. 31, 2015
Asset Impairment Charges [Abstract]
IMPAIRMENT CHARGES	IMPAIRMENT CHARGES Management conducts annual impairment reviews as of August 31, and, if conditions warrant, interim reviews of long-lived tangible and intangible assets for impairment. Before assessing whether any of the Company’s reporting units’ goodwill is impaired, the Company first assesses whether any long-lived assets were impaired. Goodwill is subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon its estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined. There were no impairment charges during 2015 During 2014, the Company’s Chemical Light reporting unit recorded a loss on impairment of certain amortizing intangible assets of $ 9.6 During the third quarter of 2014, management conducted an annual review of tangible and intangible assets for impairment. Before assessing whether any of the Company’s reporting units’ goodwill was impaired, the Company first assessed whether any long-lived assets were impaired. This assessment determined that the CTI patent asset was impaired by approximately $ 5.3 4.3

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	4. INVENTORIES Inventories, net consist of the following (all amounts in thousands): 2015 2014 Raw materials $ 4,406 $ 4,777 Work-in-process 1,809 1,546 Finished goods 1,313 1,503 $ 7,528 $ 7,826

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS 2015 2014 Prepaid expenses $ 594 $ 495 Restricted cash (1) 153 0 Other current assets 50 132 $ 797 $ 627 (1) As of December 31, 2015, the Company has cash collateralizing a letter of credit for approximately $ 153,000 February 22, 2016

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	6. PROPERTY, PLANT AND EQUIPMENT 2015 2014 Land $ 1,252 $ 1,267 Building and improvements 3,890 3,564 Machinery and equipment 8,877 8,408 Leasehold improvements 322 275 Furniture and fixtures 140 131 Software 132 132 14,613 13,777 Less: accumulated depreciation and amortization (7,818) (6,657) $ 6,795 $ 7,120

GOODWILL

GOODWILL	12 Months Ended
	Dec. 31, 2015
Goodwill, Impaired [Abstract]
GOODWILL	7. GOODWILL Goodwill represents the excess of the cost of acquiring CTI and CTSAS in 2008 and CSP and CTS in 2011 over the net fair value assigned to the assets acquired and liabilities assumed in those acquisitions, net of adjustments and impairment losses. Total CTI/CTSAS/CTS Consolidated Chemical Light CSP Goodwill Balance on December 31, 2013 (1) $ 5,014 $ 2,978 $ 7,992 Impairment loss (see Note 3) 0 0 0 Balance on December 31, 2014 (1) $ 5,014 $ 2,978 $ 7,992 Impairment loss (see Note 3) 0 0 0 Balance on December 31, 2015 (2) $ 5,014 $ 2,978 $ 7,992 (1)(2) Gross amount of goodwill was approximately $ 67.7 59.7

OTHER INTANGIBLE ASSETS

OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER INTANGIBLE ASSETS	8. OTHER INTANGIBLE ASSETS Accumulated Cost Amortization Net Book Value Developed technologies, including patents (1) $ 8,865 $ 6,903 $ 1,962 Trademarks and trade names (4) 1,070 450 620 Purchased customer relationships (2) 8,368 5,314 3,054 Non-compete agreements (3) 160 139 21 Website development costs 42 8 34 $ 18,505 $ 12,814 $ 5,691 Intangible assets as of December 31, 2014 consist of the following (all amounts in thousands): Accumulated Cost Amortization Net Book Value Developed technologies, including patents (1) $ 8,736 $ 6,582 $ 2,154 Trademarks and trade names (4) 1,068 401 667 Purchased customer relationships (2) 8,562 4,858 3,704 Non-compete agreements (3) 160 107 53 Website development costs 16 3 13 $ 18,542 $ 11,951 $ 6,591 (1) Includes a patent obtained in the acquisition of CSP with a cost of $ 50,000 17,000 5.3 (2) Includes customer relationships obtained in the acquisition of CSP with a cost of $ 920,000 60 (3) Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $ 160,000 (4) Includes CTI trademarks and trade names which were impaired by approximately $ 4.3 In 2014 certain intangible assets were found to be impaired and their cost was reduced accordingly. See Note 3 and 21 for further discussion regarding these impairments. Trademarks can be renewed without substantial cost. If trademark and trade names are not renewed, then expected future cash flows associated with trademarks and trade names could be adversely affected. Amortization of intangible assets was approximately $ 1.0 1.8 During 2015, the Company capitalized approximately $ 2,000 130,000 5,000 160,000 20 Year Ending December 31, 2016 $ 917 2017 870 2018 870 2019 800 2020 660 Thereafter 1,574 $ 5,691

DEBT ISSUANCE COSTS

DEBT ISSUANCE COSTS	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
DEBT ISSUANCE COSTS	9. DEBT ISSUANCE COSTS Debt issuance costs consist of unamortized costs paid to third parties in connection with the Company’s debt (see Note 11). Debt issuance costs are amortized to interest expense using the effective interest method. Amortization of capitalized debt issuance costs was approximately $ 240,000 42,000 The future amortization expense relating to current and noncurrent capitalized debt issuance costs is approximately $ 1.6

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	10. ACCRUED EXPENSES 2015 2014 Payroll-related (1) $ 2,727 $ 834 Interest payable 9 550 Subordinated term loan exit fee 0 285 Professional fees 101 87 Franchise and sales tax payable 18 50 Other 1,003 884 $ 3,858 $ 2,690 (1) Accrued payroll-related costs as of December 31, 2015 include approximately $ 1.8 124,000 141,000

CREDIT LINE AND NOTES PAYABLE

CREDIT LINE AND NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
CREDIT LINE AND NOTES PAYABLE	11. CREDIT LINE AND NOTES PAYABLE Monroe Refinancing On May 18, 2015, the Company entered into a credit agreement with Monroe Capital Management Advisors, LLC (the “Monroe Credit Agreement”), refinancing its existing senior and subordinated debt (see below). The Monroe Credit Agreement provides for a $ 25.0 5.0 18.0 2.0 The Monroe Credit Agreement has a term of five years and bears interest at a rate of the one-month LIBOR plus 9% 113,000 225,000 June 30, 2016 March 31, 2017 450,000 June 30, 2017 March 31, 2020 11.3 May 18, 2020 Pursuant to the terms of the Monroe Credit Agreement, the Company must maintain: a fixed charge coverage ratio of 1.25 to 1.00; (ii) a senior debt to EBITDA ratio of 4.50 to 1.00, decreasing to 1.50 to 1.00 over the term of the loans; and (iii) a twelve month trailing EBITDA, measured quarterly, in the amount of $4,750,000, increasing to $7.0 million over the term of the loans On August 3, 2015, the Company entered into a First Amendment (the “First Amendment”) to the Monroe Credit Agreement. Pursuant to the First Amendment, the Monroe Credit Agreement was amended to, among other things, reduce the aggregate amount of the Delayed Draw Loan under the Monroe Credit Agreement, which loan commitment was for purposes of funding the final payment due under the Settlement Agreement, from $ 2.0 1.5 1.4 100,000 The Delayed Draw Loan, which was drawn on August 3, 2015, provides for quarterly amortization payments on the last day of each calendar quarter in an aggregate principal amount equal to 0.625% of the original principal amount of the Delayed Draw Loan, increasing to 1.25% on March 31, 2016, and increasing to 2.5% on March 31, 2017, with the balance payable on the maturity date of May 18, 2020. In connection with the execution of the Monroe Credit Agreement, the Company issued 10 752,807.8 2.8 0.4 2.4 The proceeds from the Monroe Credit Agreement were allocated to the various instruments issued based on their relative fair value. Line of Credit The Monroe Line of Credit has a maximum borrowing capacity of $ 5.0 May 18, 2020 10 1.0 4.0 CTSAS has lines of credit, for borrowing against receivables, with a combined maximum borrowing capacity of € 750,000 820,000 Notes Payable Outstanding notes payable consist of (all amounts in thousands): 2015 2014 Monroe Term A Loan $ 17,138 $ 0 Delayed Draw Loan 1,481 0 Senior Debt - Term Loan 0 4,239 Senior Debt - Real Estate Loan 0 1,551 Subordinated Term Loan 0 9,676 Promissory Note Payable 645 860 Total 19,264 16,326 Less: Unamortized debt discount (2,756) (337) Less: Current portion of notes payable, including current portion of unamortized debt discount (492) (5,775) Notes payable, net of current portion $ 16,016 $ 10,214 Debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan. Term Loans In addition to the previous line of credit with TD Bank, CTI previously had two loans payable to TD Bank, a Term Loan and a Real Estate Loan (together, the “Senior Debt”), that were originally entered into on December 19, 2008, and which were amended twice during 2012 to modify certain financial and non-financial covenants required by these loans. The Fourth Amendment to the Amended and Restated Revolving Credit and Term Loan Agreement (the “Senior Amendment”) was entered into on November 19, 2013. On July 29, 2010, the subordinated term loan of $ 8.5 June 30, 2016 11 2,666,667 3.19 160,000 1.50 8.5 0.01 455,514 June 30, 2016 455,514 54,000 The Company’s Senior Debt and Subordinated Term Loan were refinanced on May 18, 2015. Upon the consummation of the Monroe Credit Agreement, the Company paid in full all amounts due under (i) the Amended and Restated Revolving Credit and Term Loan Agreement, dated July 29, 2010, as amended (the “Senior Credit Agreement”), by and among the Company, Cyalume Technologies, Inc. (“CTI”), certain of the Company’s other subsidiaries and TD Bank, N.A., as administrative agent and lender, (ii) the Subordinated Term Loan, dated July 29, 2010, as amended (the “Subordinated Loan Agreement”), by and among the Company, CTI, certain of the Company’s other subsidiaries, Granite Creek Flexcap I, L.P., Patriot Capital II, L.P. and Granite Creek Partners Agent, L.L.C., as administrative agent, and (iii) the amended and restated promissory note, dated November 19, 2013, as amended, previously issued by the Company to JFC Technologies, LLC (the “Amended JFC Note”) (see Note 12), such that each of the Senior Credit Agreement, the Subordinated Loan Agreement and the Amended JFC Note was paid in full and the Company has no further financial obligations thereunder. At the time of the refinancing, the Company expensed the remaining unamortized issuance costs relating to the previous Senior Debt and Subordinated Term Loan of approximately $ 0.3 Term A Delayed Loan Draw Loan Contractual interest coupon rate $ 1,131 $ 64 Amortization of related debt discount and debt issuance costs 411 31 Total interest expense recognized on the Monroe debt $ 1,542 $ 95 The effective interest rate on the Term A loan is approximately 17 20 Promissory Note Payable On November 19, 2013, the Company entered into a legal settlement agreement (see Note 16). The executed settlement agreement provided for the Company to make a series of payments to Antonio Colon in the amount of $ 215,000 1,075,000 2 Future Minimum Payments Year Ending December 31, 2016 $ 1,078 2017 1,940 2018 2,165 2019 1,950 2020 12,131 $ 19,264 Amortization of debt discount was approximately $ 661,000 205,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	12. RELATED PARTY TRANSACTIONS Financing Arrangements with Related Parties In December 2012, the Company entered into a $ 2,100,000 12 2.1 0.5 1.0 32.50 650 20 CSP leases property in Bound Brook, New Jersey, from Brook Industrial Park, LLC. This lease requires monthly lease payments of approximately $ 30,000 August 31, 2016 Bayonet Capital Fund I, LLC, Brook Industrial Park, LLC and JFC are controlled by James Schleck. On July 30, 2014, units of securities of the Company (the “Units”) were issued to Bayonet Capital Fund I, LLC (see Note 17), with each Unit comprising (1) one share of Series B Convertible Preferred Stock of the Company, par value $ 0.001

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	13. INCOME TAXES Year Ended December 31, 2015 2014 Domestic $ 2,752 $ (7,569) Foreign 732 1,091 $ 3,484 $ (6,478) Year Ended December 31, 2015 2014 Current: Federal $ (196) $ 223 State (43) 156 Foreign 310 443 Deferred: Federal (101) 2,008 State 298 (1,513) Foreign (59) (79) Provision for income taxes $ 209 $ 1,238 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The primary sources of these differences relate to the carrying value of identified intangible assets, inventories, fixed assets, certain accruals and reserves. December 31, 2015 December 31, 2014 Non-current Current Non-current Deferred tax assets: Federal $ 13,285 $ 2,699 $ 11,857 State 1,763 777 1,426 Foreign 0 0 0 Less: valuation allowance (12,243) (2,741) (10,353) 2,805 735 2,930 Deferred tax liabilities: Federal (2,385) (805) (2,103) State (616) (219) (538) Foreign (371) (16) (414) (3,372) (1,040) (3,055) Deferred tax assets (liabilities) $ (567) $ (305) $ (125) Principal components of our net liability representing deferred income tax balances are as follows (all amounts in thousands): December 31, 2015 2014 Intangible assets $ 566 $ 178 Property, plant and equipment (622) (661) U.S. loss carryforwards and tax credits, net (1) 10,004 10,151 Subsidiary income (2) (700) (764) Stock-based compensation expense 1,243 1,142 Reserves, accruals and other 430 1,664 State deferred tax asset 755 954 Valuation allowance (12,243) (13,094) $ (567) $ (430) (1) The Company had federal net operating loss carryforwards amounting to approximately $ 4.6 3.9 2027 2035 0.4 8.4 10.3 (2) A deferred tax liability has been recorded for income taxes which may become payable upon distribution of earnings of CTSAS, our French subsidiary. The estimated amount of tax that might be payable with regard to any distribution for foreign subsidiary earnings is reported net of foreign taxes paid, which are creditable against our domestic tax liability. The Company does not permanently reinvest foreign subsidiary earnings. The Company continually evaluates this assertion; if the Company’s foreign business needs change, so may this assertion. Year Ended December 31, 2015 2014 Provision for (benefit) from federal income taxes expected at 34% statutory rate $ 1,184 $ (2,201) Increase (reduction) resulting from: Tax on global activities, net of foreign tax credits (394) (2,842) State income taxes, less federal income tax benefit 168 (895) Loss on debt extinguishment 0 179 Change in valuation allowance (851) 7,172 Change in fair value of warrants 10 (1,518) Legal settlement (470) 0 Prior year true up 534 1,008 Other 28 335 Provision for income taxes $ 209 $ 1,238

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	14. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Currency Forward Contracts CTSAS’ functional currency is the Euro. Periodically, CTSAS purchases inventory from CTI, which requires payment in U.S. dollars. Beginning in 2009, and only under certain circumstances, the Company utilizes currency forward contracts to mitigate CTSAS’ exposure to changes in the Euro-to-U.S. dollar exchange rate upon payment of these inventory purchases. Such currency forward contracts typically have durations of less than six months. These currency forward contracts are reported at their fair value. This relationship has not been designated as a hedge and therefore all changes in these currency forward contracts’ fair value are recorded in other income, net within the accompanying consolidated statements of comprehensive income (loss). There were no currency forward contracts outstanding at December 31, 2015 or December 31, 2014.

ASSET RETIREMENT OBLIGATION

ASSET RETIREMENT OBLIGATION	12 Months Ended
	Dec. 31, 2015
Asset Retirement Obligation Disclosure [Abstract]
ASSET RETIREMENT OBLIGATION	ASSET RETIREMENT OBLIGATION Annual inflation rate 5.54 % Credit-adjusted risk-free rate 5.37 % Initial estimated remediation costs (undiscounted and not adjusted for inflation) $200,000 ($41,000 paid in 2007) Estimated remediation completion date December 19, 2038 Estimated remediation cost on December 19, 2038 $ 720,000 Year Ended December 31, 2015 2014 Balance, beginning $ 204 $ 194 Accretion expense 10 10 Balance, ending $ 214 (1) $ 204 (1) The difference between the $214,000 liability as of December 31, 2015 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2015 and December 19, 2038. Accretion expense on the asset retirement obligation is included in general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES Operating Leases The Company leases certain equipment, automobiles and other assets under cancelable and non-cancelable operating leases. Expenses associated with these leases totaled approximately $ 725,000 756,000 Included in these leases is a market-based, related-party lease which CSP assumed in conjunction with the business combination. CSP entered into the lease with an entity controlled by one of our stockholders for industrial-use property located in Bound Brook, New Jersey, U.S.A. The lease ends on August 31, 2016, with extension options available, and requires lease payments of $ 24,000 30,000 Year Ending December 31, 2016 $ 543 2017 279 2018 100 2019 32 2020 0 $ 954 Legal From time to time and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. At December 31, 2015 and 2014 (see the description of the legal settlements below), the Company did not have any pending claims, charges, or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations, or cash flows. Civil Action No. 06-706 in Superior Court of the Commonwealth of Massachusetts On January 23, 2006, before the Company owned CTI, the former owners of CTI (from whom CTI was purchased) (the “Former Owners”) acquired all of the outstanding capital stock of Omniglow Corporation (the “Transaction”) and changed the name of the company to Cyalume Technologies, Inc. Prior to, or substantially simultaneously with, the Transaction, CTI sold certain assets and liabilities related to Omniglow Corporation’s novelty and retail business to certain former Omniglow Corporation stockholders and management (“the Omniglow Buyers”). This was done because CTI sought to retain only the Omniglow Corporation assets and current liabilities associated with its government, military and safety business. During 2006, CTI and the Omniglow Buyers commenced litigation and arbitration proceedings against one another. Claims include breaches of a lease and breaches of various other agreements between CTI and the Omniglow Buyers. These proceedings are known as Civil Action No. 06-706 in Superior Court of the Commonwealth of Massachusetts (the “Court”). On December 19, 2008, while Civil Action 06-706 was still unresolved, the Company acquired CTI (the “Acquisition”). According to the Stock Purchase Agreement between the Former Owners and the Company, the Former Owners retained the responsibility for paying for all costs and liabilities associated with Civil Action No. 06-706. On July 18, 2011, CTI received an Order for Entry of Final Judgment in Civil Action No. 06-706 in which the Court awarded approximately $ 2.6 12 1.3 235,000 12 On July 12, 2012, the Court issued an Amended Final Judgment and, on September 20, 2012, a Final Judgment. There were no changes to the previously described damage awards. In response, on October 17, 2012, the Company filed a Notice of Appeal and on August 2, 2013, the Company filed a Formal Appeal, which contains a number of bases for overturning the awards. Oral arguments were made by the parties before the Appellate Court during January of 2014. In May 2014, the Company received notice that its appeal of the Final Judgment had been denied. On July 1, 2014, CTI filed an Application for Further Appellate Review in the Massachusetts Supreme Judicial Court. The Former Owners (1) previously retained the responsibility for paying the costs and liabilities associated with Civil Action No. 06-706 and (2) are related parties under U.S. GAAP due to their ownership interest in the Company and their membership on the Company’s board of directors. On November 19, 2013, a Release and Escrow Agreement was executed whereby the Company released affiliates of the Former Owners from being obligated on the costs and liabilities associated with Civil Action No. 06-706 in exchange for 625,139 shares of Cyalume stock placed in escrow (the “Escrowed Shares”). During 2013, 625,139 625,139 On July 10, 2014, the Company entered into a Confidential Settlement Agreement and Mutual Release (the “Omniglow Settlement Agreement”) with the Former Owners and members of management of Omniglow Corporation (collectively, the “Omniglow Buyers”). Pursuant to the Omniglow Settlement Agreement, CTI agreed to either pay the full settlement amount of approximately $4.5 million or satisfy the settlement amount as follows: (i) an initial payment of $250,000, (ii) transfer the 625,139 Escrowed Shares, (iii) payment of $1.0 million in cash within 21 days from the execution of the Omniglow Settlement Agreement and (iv) additional payments in cash and/or through cooperative marketing credits of $1.9 million if paid within 18 months from the date of the Omniglow Settlement Agreement, or of approximately $2.4 million if paid within 27 months from the date of the Omniglow Settlement Agreement. Effective as of August 3, 2015, CTI entered into a Second Amendment (the “Settlement Amendment”) to the Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) entered into on July 10, 2014 (the “Settlement Agreement”), with certain former stockholders and members of management of Omniglow Corporation (collectively, the “Omniglow Buyers”) (which Settlement Agreement was summarized in the Current Report on Form 8-K filed by the Company on July 16, 2014). Pursuant to the Settlement Amendment, the parties to the Settlement Agreement agreed to amend CTI’s obligation to make the final settlement payment due under the Settlement Agreement, such that CTI would make a final payment of $ 1.4 1.9 2.35 Settlement of Arbitration with Former Employee On December 22, 2011, CTI entered into a Stock Purchase Agreement (“SPA”) with Combat Training Solutions, Inc. (“CTS”) and Antonio Colon, the sole stockholder of CTS. Pursuant to the SPA, CTI purchased all of the issued and outstanding capital stock of CTS. On June 15, 2012, the Company received a copy of a demand for arbitration filed by Mr. Colon with the American Arbitration Association. Management considered the allegations by Mr. Colon to be without merit. On August 17, 2012, Mr. Colon filed suit in Federal Court and on September 11, 2012, he filed to have the arbitration withdrawn. In addition, on September 11, 2012, Mr. Colon chose to cease working for the Company. CTI filed a Motion to Dismiss the Complaint in Federal Court and to compel the controversy to arbitration before the American Arbitration Association. The District Court for the District of Delaware held a hearing on January 23, 2013, at which it dismissed the Complaint in Federal Court without prejudice and indicated that the arbitration should proceed. On September 23, 2013, the parties entered into an agreement to resolve this matter, and a settlement agreement was signed on November 19, 2013. The executed settlement agreement provides for the Company to make a series of payments over five years to Mr. Colon in the amount of $ 215,000 1,075,000 275 215,000

PREFERRED STOCK

PREFERRED STOCK	12 Months Ended
	Dec. 31, 2015
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
PREFERRED STOCK	17. PREFERRED STOCK Series A Convertible Preferred Stock The Company is authorized to issue 1,000,000 On November 19, 2013, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with US VC Partners, L.P. (the “Series A Investor”) for the purchase by the Investor of 123,077 4.0 32.50 0.001 Each share of Series A Preferred Stock may be converted at any time at the option of the holder into a number of shares of common stock initially equal to 50 0.65 0.13664587 Upon voluntary or involuntary liquidation, dissolution or winding up of the Company, each holder of Series A Preferred Stock is entitled to a liquidation preference of $ 32.50 Dividends on the Series A Preferred Stock accrue (payable in cash or in kind), whether or not declared by the Board and whether or not funds are available for the payment of dividends, at a rate of 12 Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of shares of common stock into which such share is convertible and shall be entitled to vote with holders of outstanding shares of common stock, voting together as a single class, with respect to any and all matters presented to the stockholders of the Company for their action or consideration. The requisite holders of the Series A Preferred Stock will have the right to cause the Company to redeem, out of funds legally available, all but not less than all of the then outstanding shares of Series A Preferred Stock, for a price per share equal to the Series A Liquidation Value of such shares from and after the fifth anniversary of the closing date of the Series A Purchase Agreement. Additionally, the Company will have the right to redeem all of the outstanding shares of Series A Preferred Stock from and after the eighth anniversary of the closing date of the Series A Purchase Agreement at a redemption price equal to the Series A Liquidation Value. As a result of the redemption provisions, the Series A Preferred Stock has been classified outside of permanent equity. The significant change in the conversion price of the Series A Preferred Stock was determined to be a substantive qualitative change of a conversion feature that is reasonably possible of being exercised. Therefore, the amendment to the terms of the Series A Preferred Stock made on July 30, 2014 was accounted for as an extinguishment in accordance with the derecognition accounting model under ASC 260-10-S99-2. The Series A Preferred Stock fair value on the extinguishment date was estimated at approximately $ 1.6 2.4 Series B Convertible Preferred Stock On July 30, 2014, the Company entered into a Securities Purchase Agreement (the “Series Band C Purchase Agreement”) with Cova Small Cap Holdings, LLC (“Cova”), Bayonet Capital Fund I, LLC (see Note 12), and another investor (each, an “Investor”) for the purchase by the Investors of an aggregate of 1,000 2.0 2,000 0.001 0.001 1.3 Civil Action No. 06-706 The shares of Series B Preferred Stock have the rights and preferences set forth in the Certificate of Designation of Series B Convertible Preferred Stock, which was amended on May 15, 2015 (the “Amended Series B Certificate of Designation”). Pursuant to the Amended Series B Certificate of Designation, each share of Series B Preferred Stock ranks senior to the Company’s common stock (the “Common Stock”) and the Company’s Series A Preferred Stock with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up of the Company. Upon the Company’s liquidation, sale to or merger with another corporation or other “Change of Control” (as such term is defined in the Amended Series B Certificate of Designation), each share of Series B Preferred Stock would be entitled to a liquidation preference in an amount equal to the amount per share that would have been payable had all shares of Series B Preferred Stock been converted into Common Stock immediately prior to such event in accordance with the terms of the Amended Series B Certificate of Designation, excluding for purposes of such calculation the liquidation preference payable to the holders of Series A Preferred Stock. Holders of the Series B Preferred Stock are entitled to convert at any time all or any portion of the shares of Series B Preferred Stock into a number of shares of Common Stock initially equal to 35,713.147 if the Company issues or sells shares of Common Stock or other equity securities for no consideration or for consideration that is based on an equity valuation of the Company of less than $ 2.0 In connection with the issuance of the Series B Preferred Stock and the Series C Preferred Stock on July 30, 2014, the Company allocated the aggregate proceeds of $ 2.0 1.4 0.6 2.5 1.1 Series C Preferred Stock The shares of Series C Preferred Stock have the rights and preferences set forth in the Certificate of Designation of Series C Preferred Stock, which was amended on May 15, 2015 (the “Amended Series C Certificate of Designation”). Pursuant to the Amended Series C Certificate of Designation, each share of Series C Preferred Stock ranks senior to the Common Stock, the Series A Preferred Stock, the Series B Preferred Stock and the Series D Preferred Stock with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up of the Company. Upon the Company’s liquidation, sale to or merger with another corporation or other “Change of Control” (as such term is defined in the Amended Series C Certificate of Designation), each share of Series C Preferred Stock would be entitled to a liquidation preference equal to the sum of: (1) $ 3,000 12 2,000 75 The proceeds allocated to the Series C Preferred Stock fair on the issuance date were estimated at approximately $ 0.6 1.4 Series D Preferred Stock In connection with the execution of the Monroe Credit Agreement, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with Monroe Capital Corporation, Monroe Capital Senior Secured Direct Loan Fund LP, Monroe Capital Senior Secured Direct Loan Fund (Unleveraged) LP and Monroe Capital Partners Fund II, LP. Pursuant to the Subscription Agreement, the Company issued 10 0.001 752,807.8 In the event of any voluntary or involuntary liquidation, the holders of the Series D Convertible Preferred Stock shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of junior securities. The Series C Preferred Stockholders would receive the Base Liquidation Value first, and not be entitled to the Excess Liquidation Value (as defined in the Amended Certificate of Designation of the Series C Preferred Stock) until the holders of the Series D Convertible Preferred Stock receive a pro rata Liquidation Value amount in cash. If at any time the Company redeems the outstanding shares of Series A Preferred Stock or Series C Preferred Stock, the holders of the Series D Preferred Stock would have the right to elect to cause the Company to redeem, out of funds legally available therefore, all but not less than all of the then outstanding shares of Series D Preferred Stock, for a price per share equal to the Liquidation Value for such shares; provided that, prior to the Company paying the full redemption price for all outstanding shares of Series D Preferred Stock, the Company would not be permitted to pay (i) any amounts in excess of the Series C Base Liquidation Value upon the redemption of shares of Series C Preferred Stock or (ii) any amounts upon the redemption of shares of Series A Preferred Stock. In the event of a voluntary or involuntary liquidation, each share of Series D Preferred Stock would be entitled to a liquidation preference in an amount equal to the amount per share that would have been payable had all shares of Series D Preferred Stock been converted into Common Stock immediately prior to such event in accordance with the terms of the Series D Certificate of Designation, excluding for purposes of such calculation the liquidation preference payable to the holders of Series A Preferred Stock and the holders of Series B Preferred Stock. The Series D Preferred Stock does not have any voting rights, except that the written consent of the holders of a majority of the then-outstanding Series D Preferred Stock shall be required for the Company to take certain actions, including the amendment of its certificate of incorporation or bylaws in a manner that adversely affects the relative rights, preferences, privileges or powers of holders of Series D Preferred Stock. As a result of the redemption provisions, the Series D Convertible Preferred Stock has been classified outside of permanent equity. In connection with the Monroe refinancing transaction and the issuance of the Series D Preferred Stock, the Company allocated approximately $ 2.8

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock The Company is authorized to issue 150,000,000 Common and Preferred Warrants Common stock purchase warrants accounted for within equity are recorded at their initial fair value and reported in stockholders’ equity as increases to additional paid-in capital. Warrants reported as equity, rather than liabilities (i) may not be net-cash settled, (ii) have contractual limits on the number of shares to be delivered in a net-share settlement and (iii) are supported by sufficient unissued common shares available to settle the outstanding warrants. Subsequent changes in fair value from the warrants’ initial fair value are not recognized as long as the warrants continue to merit classification as equity. During 2012, warrants to purchase 160,000 455,514 Pursuant to the terms of a letter agreement previously entered into between the Company and Dragonfly Capital Partners, LLC (“Dragonfly”) under which Dragonfly provided advisory services to the Company in connection with the Company’s debt financing, the Company paid $ 820,000 1,003,744 0.05 The estimated fair value of the Dragonfly Warrant was recorded as an issuance cost in connection with the Monroe refinancing transaction. Stock price of underlying equity $ 0.05 Exercise price $ 0.05 Expected term (years) 5.0 Risk-free interest rate 1.5 % Estimated dividend yield None Volatility 157.0 % The Dragonfly Warrant was reflected at its relative fair value of approximately $43,000 in connection with the Monroe refinancing transaction. Warrants to purchase the Company’s common stock were outstanding as follows as of December 31, 2015: Number of Number of Shares Shares Exercisable Under Under Exercise Expiration Warrant Holder Warrant Warrant Price Date Granite Creek FlexCap I, L.P. (“Granite”) 267,950 267,950 $ 0.01 November 19, 2023 Patriot Capital II, L.P. (“Patriot”) 187,564 187,564 $ 0.01 November 19, 2023 Dragonfly Capital Partners, LLC (“Dragonfly”) 1,003,744 1,003,744 $ 0.05 May 18, 2020 Granite and Patriot Warrants Stock price of underlying equity $ 0.12 Exercise price $ 0.01 Expected term (years) 7.9 Risk-free interest rate 2.2 % Estimated dividend yield None Volatility 167.0 % Granite and Patriot Warrants (see Note 11) Warrant liability at December 31, 2014 $ 25 Change in fair value of warrants 29 Warrant liability at December 31, 2015 $ 54 Share-Based Compensation On March 3, 2009, the Company’s Board of Directors adopted the Cyalume Technologies Holdings, Inc. 2009 Omnibus Securities and Incentive Plan (the “2009 Plan”). The Plan was approved during the Company’s Annual Meeting of Stockholders on June 18, 2009. On October 7, 2014, the Company’s Board of Directors adopted the Cyalume Technologies Holdings, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved on February 15, 2015. The purpose of the 2009 Plan and the 2014 Plan is to benefit stockholders by assisting the Company in attracting, retaining and providing incentives to key management employees and non-employee directors of, and non-employee consultants to, Cyalume Technologies Holdings, Inc. and its subsidiaries, and to align the interests of such employees, non-employee directors and non-employee consultants with those of stockholders. Accordingly, the 2009 Plan and the 2014 Plan both provide for the granting of Distribution Equivalent Rights, Incentive Stock Options, Non-Qualified Stock Options, Performance Share Awards, Performance Unit Awards, Restricted Stock Awards, Stock Appreciation Rights, Tandem Stock Appreciation Rights, Unrestricted Stock Awards or any combination of the foregoing, as may be best suited to the circumstances of the particular employee, director or consultant as provided therein. Under the 2009 Plan, the Company was authorized to issue up to 2,650,000 10,000,000 1,149,082 2,885,582 Share-based awards are also issued that are not under either the 2009 Plan or the 2014 Plan. In September 2012, the Company awarded options to purchase the Company’s common stock to the Chief Operating Officer and the Chief Executive Officer. These options were not awarded under the 2009 Plan and these options were canceled on November 21, 2014. The Company accounted for the cancellation of these two officer awards and the concurrent grant of the replacement awards as a modification of the terms of the cancelled awards. The Company determined the incremental compensation cost by comparing the fair value of the replacement awards to the fair value of the cancelled awards on November 21, 2014. The remaining unamortized compensation cost of approximately $ 0.4 These two canceled awards were replaced with options to the Chief Operating Officer to purchase 1,504,767 5,015,891 0.09 During the years ended December 31, 2015 and 2014, total expense recorded for share-based compensation was approximately $ 404,000 394,000 Year Ended December 31, 2015 2014 Cost of revenues $ 11 $ 9 Sales and marketing 32 38 General and administrative 334 331 Research and development 27 16 $ 404 $ 394 The Company does not currently possess any treasury shares; therefore any issuance of stock for any share-based compensation award is expected to be from new shares. Stock Option Awards The Black-Scholes pricing model is used to value stock options awarded as share-based compensation. The expected term of the options awarded under share-based compensation arrangements individually is estimated based on the estimated term of the award, the exercise price of the award, the estimated risk-free interest rate over the award’s estimated term, estimated annual dividend yield, and the estimated volatility of the price of our common stock over the award’s estimated term. Risk-free interest rate assumptions are based on U.S. Treasury securities issued with maturities similar to the expected terms of the awards. In September 2012, the Company began estimating the future volatility of the price of our common stock using historical daily prices of our common stock; before September 2012, since our common stock had insufficient trading history to estimate future price volatility, volatility was using historical data of another public company operating in our industry. 2015 2014 Expected term (years) 6.0 – 6.3 6.3 – 10.0 Risk-free interest rate 1.61 – 1.74 % 1.83 – 2.31 % Estimated dividend yield None None Volatility 161.01 – 165.83 % 143.89 – 144.45 % Stock options awarded will generally vest in zero to five years. Options awarded to executive officers and other management often may be earned based on meeting Board-determined or CEO-determined performance goals unique to each award recipient and require continued employment over the vesting period. Options awarded to members of the Board of Directors typically vest on the grant date. Options awarded typically expire 10 years after the grant date. Shares Weighted Average (in thousands) Exercise Price Outstanding at December 31, 2014 2,852 $ 2.10 Granted (1) 9,197 0.09 Exercised 0 0 Forfeited/Canceled (1,520) 1.52 Expired (182) 3.04 Outstanding at December 31, 2014 10,347 0.38 Granted (2) 250 0.14 Exercised 0 0 Forfeited/Canceled (41) 0.09 Expired (1) 3.65 Outstanding at December 31, 2015 (3) 10,555 $ 0.38 Exercisable at December 31, 2015 (4) 3,853 $ 0.76 (1) The weighted-average grant-date fair value of awards granted was $ 0.09 (2) The weighted-average grant-date fair value of awards granted was $ 0.13 (3) The aggregate intrinsic value of these stock options is approximately $ 277,000 8.54 (4) The aggregate intrinsic value of these stock options is approximately $ 90,000 8.01 As of December 31, 2015, there was approximately $ 502,000 2.67 Restricted Stock The Company values stock awards at the closing market price of the underlying shares on the trading day previous to the grant date, adjusted for expected forfeitures. There were no unvested restricted stock awards outstanding as of December 31, 2015. Accumulated Other Comprehensive Loss Accumulated other comprehensive loss relates to foreign currency translation adjustments. Balance, December 31, 2013 $ (218) Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars (443) Balance, December 31, 2014 (661) Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars (318) Balance, December 31, 2015 $ (979)

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS 211,000 58,000 French law requires companies within France (such as CTSAS) to pay its workers a benefit, based on various factors, when an employee becomes 65 years old. The Company estimated the present value of such a liability for employees at CTSAS and approximately $ 81,000 78,000

CONCENTRATIONS

CONCENTRATIONS	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
CONCENTRATIONS	20. CONCENTRATIONS Sales Concentrations In 2015, approximately 37 41 Geographic Concentrations The Company sells to customers located in the United States of America and in international markets. Revenues to customers outside the United States represent approximately 31 52 7 12 CTSAS’ operations are our only operations outside the United States of America. CTSAS’ net assets were approximately $ 2,853,000 3,362,000 Concentrations of Credit Risk Arising from Financial Instruments As of December 31, 2015, three customers combined represented approximately 53 10 49 10 The Company maintains cash in several different financial institutions in amounts that typically exceed U.S. federally insured limits and in financial institutions in international jurisdictions where insurance is not provided. The Company has not experienced any losses in such accounts and the Company believes it is not exposed to significant credit risk. Beginning in 2013, insurance coverage reverted to $ 250,000 financial institution and as of December 31, 2015, the cash balances 0.6 0.6

FAIR VALUES OF ASSETS AND LIABI

FAIR VALUES OF ASSETS AND LIABILITIES	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUES OF ASSETS AND LIABILITIES	FAIR VALUES OF ASSETS AND LIABILITIES Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Quoted Prices in Active Level 2 Markets Significant Level 3 Assets/ for Other Significant (Liabilities) Identical Observable Unobservable At Fair Assets Inputs Inputs Value Warrants (see Note 18) (1) $ 0 $ 0 $ (54) $ (54) $ 0 $ (0) $ (54) $ (54) (1) The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method. Year Ended December 31, 2015 2014 Warrants liability: Balance at the beginning of period $ 25 $ 6,373 Warrants amended in connection with refinancing 0 72 Warrant exercise 0 (44) Termination of common and preferred warrants 0 (1,524) Change in fair value of warrants 29 (4,852) Balance at the end of period $ 54 $ 25 The Company has other financial instruments, such as cash, accounts receivable, due from related party, accounts payable, notes payable and a line of credit. The Company believes the carrying amounts of those assets and liabilities approximate their fair value since those carrying amounts have been estimated to approximate the exit price which would be received to sell these assets or pay to transfer these liabilities to a market participant. See Note 2 for a discussion of our accounting policy regarding fair value. During the year ended December 31, 2015, no assets were identified as impaired. During the year ended December 31, 2014, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3): Cyalume Reporting Unit (1) Loss Recognized Fair Value Patents (2) Chemical Light $ 5,277 $ 2,154 Trade name (3) Chemical Light 4,303 667 (1) The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.). (2) The fair value of the impaired patent asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach). (3) The fair value of the impaired trademarks and trade names asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).

SUPPLEMENTAL DISCLOSURE OF CASH

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	22. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash Paid for Interest and Income Taxes (all amounts in thousands): Year Ended December 31, 2015 2014 Interest $ 1,558 $ 592 Income taxes 801 244 (all amounts in thousands): Year Ended December 31, 2015 2014 Series A Convertible Preferred stock accrued dividend $ 573 $ 509 Series C Preferred stock accrued dividend 264 103 Issuance of Series D Convertible Preferred stock in connection with debt refinancing 2,751 0 Relative fair value of warrant issued in connection with debt refinancing 43 0 Series A, Series B and Series C Preferred stock deemed dividends 0 4,921 Adjustment to warrant liability upon warrant exercise 0 44 Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP 0 241 Issuance of 242,308 shares to related party 0 157

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	23. SUBSEQUENT EVENTS Pursuant to the terms of the Monroe Credit Agreement, the Company made an excess cash payment of approximately $ 247,000

SIGNIFICANT ACCOUNTING POLICI31

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Foreign Operations	Foreign Operations The accounting records of our France-based subsidiary CTSAS are maintained in Euros, their local and functional currency. For consolidation, revenue and expense transactions are translated to U.S. dollars using the average exchange rate of the month in which the transaction took place. Assets and liabilities are translated to U.S. dollars using the exchange rate in effect as of the balance sheet date. Equity transactions are translated to U.S. dollars using the exchange rate in effect as of the date of the equity transaction. Translation gains and losses are reported as a component of accumulated other comprehensive income (loss) within stockholders’ equity. Gains and losses resulting from transactions which are denominated in other than the functional currency are reported as other income or loss in the statement of comprehensive income (loss) in the period the gain or loss occurred.
Reclassifications	Reclassifications Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to the Company’s historical classification of legal settlement payments from financing activities to operating activities in the statement of cash flows. Historically, the Company classified cash flows associated with obligations relating to the Omniglow Settlement Agreement as cash flows from financing activities based on the presence of financing elements in the Omniglow Settlement Agreement. However as these obligations also possess elements of operating activities, the Company has determined that it will classify the related cash flows as cash flows from operating activities. Accordingly, prior period amounts were reclassified in the Consolidated Statements of Cash Flows to conform to the current year presentation. See Note 16 – Commitments and Contingencies for additional information pertaining to these legal settlement payments.
Comprehensive Income (Loss)	Comprehensive income (loss) accounts for changes in stockholders’ equity resulting from non-stockholder sources. All transactions that would cause comprehensive income (loss) to differ from net income (loss) have been recorded and disclosed and relate to the translation of the accounting records of our France-based subsidiary CTSAS.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are used when accounting for certain items such as reserves for inventory, accounts receivable and deferred tax assets; assessing the carrying value of intangible assets including goodwill; determining the useful lives of property, plant and equipment and intangible assets; determining asset retirement obligations ; and estimating parameters and assumptions used to determine the fair values of warrants and preferred stock
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the aggregate unpaid amount less any allowance for doubtful accounts. The allowance is based on historical bad debt experience and the specific identification of accounts deemed uncollectible. An account receivable’s delinquency status is determined based on its contractual terms. Interest is not charged on outstanding balances. Accounts are written off only when all methods of recovery have been exhausted. Credit risk is controlled through initial credit evaluations and approvals, credit limits, and monitoring procedures. Ongoing credit evaluations of customers are performed but do not require collateral to secure accounts receivable.
Inventories	Inventories Inventories are stated at the lower of cost (on a first-in first-out (“FIFO”) method) or net realizable value. The cost of inventory consists of raw material content, labor costs to produce the inventory and overhead costs incurred during production of the inventory. The Company periodically reviews the realizability of inventory. Provisions are recorded for potential obsolescence which requires management’s judgment. Conditions impacting the realizability of inventory could cause actual write-offs to be materially different than provisions for obsolescence.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost. Depreciation is computed under the straight-line method over the estimated useful lives of four to eight years for equipment and 30 Property, plant and equipment assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Such reviews are based on a comparison of the asset’s undiscounted cash flows to the recorded carrying value for the asset. Impairment charges, if any, are recorded in the period in which the impairment is determined.
Goodwill	Goodwill Goodwill is deemed to have an indefinite life and accordingly, is not subject to amortization. Goodwill is subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon its estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined. The Company performs a traditional two-step process for assessing goodwill for impairment annually. The first step of the two-step process requires a comparison of estimated fair value for each reporting unit versus the carrying or book value. If the carrying value exceeds fair value, further analysis (step 2 of the two-step process) is required to determine the amount, if any, that goodwill is impaired. Fair value is determined using a discounted cash flow analysis.
Intangible Assets	Intangible Assets Intangible assets include developed technologies and patents, customer relationships, non-compete agreements, trademarks and trade names, all of which are amortized over their estimated useful lives. The carrying amounts of amortizing intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Costs incurred to register new patents or defend existing patents are capitalized, while costs to renew or extend the term of intangible assets are expensed when incurred. Costs incurred with third parties that are related to internally developing or successfully defending an intangible asset are capitalized as part of the intangible asset developed or defended and amortized over that asset’s remaining useful life. Such costs with third parties related to patent or trademark applications that are ultimately rejected by the relevant government authority are expensed upon rejection. Useful lives Patents and developed technologies (1) Purchased customer relationships 9 – 13 years Trademarks and trade names (2) Non-compete agreements 5 years (1) Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 5.3 (2) Trademarks and trade names of CTI are deemed to have a useful life of 15 4.3
Debt Issuance and Deferred Financing Costs	Debt Issuance and Deferred Financing Costs Costs paid to lenders to obtain financing are presented as discounts on the related debt and are amortized to interest expense over the term of the related financing, using the effective interest method (unless the financing is a line of credit, in which case the straight-line method is used). Such costs paid to third parties are presented as assets and are amortized to interest expense in the same manner as costs paid to lenders.
Derivatives	Derivatives Derivatives are recorded at their fair value as of the balance sheet date. If a derivative qualifies for “hedge accounting” under U.S. GAAP and has been designated as a hedge by us, then the “effectively hedged” portion is recorded, as defined by U.S. GAAP, of changes in such derivatives’ fair value in accumulated other comprehensive loss, which is a component of our stockholders’ equity. The Company records (i) ineffectively hedged portions of such changes in fair value or (ii) changes in the fair value of derivatives not designated as a hedge in our consolidated statement of comprehensive loss in the period the change occurred. On the consolidated statement of cash flows, cash flows from derivative instruments accounted for as cash flow hedges are classified in the same category as the cash flows from the items being hedged.
Warrants Liability	Warrants Liability The Company uses fair values as determined by significant unobservable inputs. These estimated values are significant inputs into the Monte Carlo simulation method and the Black Scholes pricing model used to calculate the estimated fair value of common warrants and preferred warrants potentially settleable in cash, which are recorded as warrants liability. The estimated fair value of the common warrants and the preferred warrants are determined at each balance sheet date and the change in the estimated fair value of the warrants is reflected within the Company’s statements of comprehensive income (loss). Certain common and preferred warrants were terminated on July 30, 2014.
Revenue Recognition	Revenue Recognition Revenue from the sale of products or the providing of services is recognized when the earnings process is complete, the amount of recognizable revenue can be determined, the risks and rewards of ownership have transferred to the customer and collectability is reasonably assured. Depending on the terms of the individual sales arrangement with our customer, product sales are recognized at either the shipping point or upon receipt by the customer. Costs and related expenses to manufacture the products are recorded as costs of goods sold when the related revenue is recognized. Additionally, if the right of return is granted to the buyer in a product sale, revenue is deferred until enough historical customer data is available to reasonably estimate returns and related costs. Certain contracts provide for the sale of indefinite quantities of products at fixed per unit prices, subject to adjustment for certain economic factors. Revenue under these contracts is recognized when products ordered under the contracts are received by the customer. Whenever costs change, the pricing under these contracts is reviewed to determine whether they require the sale of products at a loss. To date, there are no loss contracts which would require the accrual of future losses in the current financial statements. Research and development services are provided for customers for which the Company earns payments that are contingent upon achieving a specific result (“milestones”). Upon achieving such milestones, revenue is recognized provided that the payment is (i) related to past performance, (ii) reasonable relative to all of the deliverables and payment terms within the arrangement with our customer, and (iii) nonrefundable.
Taxes Collected from Customers	Taxes Collected from Customers Sales taxes collected from customers are not considered revenue and are included in accounts payable and accrued expenses until remitted to the taxing authorities.
Shipping and Handling Costs	Shipping and Handling Costs Outbound shipping and handling costs are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). These costs were approximately $ 231,000 358,000
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). Advertising expense was approximately $ 67,000 151,000
Stock-Based Compensation	Stock-based compensation is incurred related to awards of common stock, restricted common stock and options to employees and non-employees. Those awards granted to employees are measured at their fair value on the date the award is granted and are recognized in our consolidated financial statements over the period the grantee is required to provide services in exchange for the award. When recognized as an expense, the fair value of the award, less estimated forfeitures, is recognized on a straight-line basis over the award service period; if there is no such service period, then the entire fair value of the award is recognized as expense on the grant date. The fair value of share-based payments to non-employees is estimated at each reporting period, until a measurement date is reached, and recorded as expense over the service period.
Research and Development	Research and Development The Company has research and development groups with full-time chemists and engineers at both the West Springfield and Bound Brook facilities. The research and development groups are focused on maintaining quality of existing products, developing improvements to existing products, and developing new technologies and products with viable commercial applications. Research and development costs are expensed as incurred.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are recognized when, based upon available evidence, realization of the assets is more likely than not. In assessing the realization of long-term deferred income tax assets, it is considered whether it is more likely than not that the deferred income tax assets will be realized. The realization of deferred income tax assets depends upon future taxable income in years before net operating loss carryforwards expire. The recoverability of deferred income tax assets is evaluated on a quarterly basis. If the Company determines that it is more likely than not that deferred income tax assets will not be recovered, a valuation allowance is established against some or all deferred income tax assets. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceeds the amount measured as described above, if such a position existed, would be reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. There were no such positions as of December 31, 2015 or 2014. Interest on tax deficiencies is classified as interest expense and income tax penalties are classified as other expense. In September 2015, the IRS completed an audit of our tax return for the year 2013. There were no adjustments to our 2013 tax return. Our tax return filed for the year 2014 is still open for audit. The tax return for 2014 was filed on September 14, 2015 under a filing extension. The tax return for 2015 is expected to be filed under a filing extension prior to September 15, 2016.
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share Basic earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the basic weighted average number of common shares outstanding. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. (in thousands, except shares and per share information) Year Ended December 31, 2015 2014 Numerator (in thousands): Net income (loss) $ 3,275 $ (7,716) Series A convertible preferred stock dividends (573) (509) Series C preferred stock dividends (264) (103) Series A deemed dividend 0 (2,422) Series B deemed dividend 0 (1,098) Series C deemed dividend 0 (1,401) Net income (loss) available to common stockholders – basic $ 2,438 $ (13,249) Effect of dilutive securities: Add: Convertible related party promissory note 45 0 Add: Series A convertible preferred stock dividends 573 0 Income (loss) available to common stockholders – diluted $ 3,056 $ (13,249) Denominator: Weighted average common shares outstanding – basic 21,400,244 21,294,432 Weighted average effect of dilutive common equivalent shares: Assumed conversion of Series A convertible preferred stock 37,598,865 0 Assumed conversion of Series B convertible preferred stock 35,713,147 0 Assumed conversion of Series D convertible preferred stock 4,661,221 0 Convertible related party note 2,766,876 0 Warrants 234,214 0 Options 1,478 0 Weighted average common shares outstanding – diluted 102,376,045 21,294,432 Earnings (loss) per common share: Basic $ 0.11 $ (0.62) Diluted $ 0.03 $ (0.62) Year Ended December 31, 2015 2014 Options 10,505,322 10,347,322 Series A convertible preferred stock 0 33,401,765 Series B convertible preferred stock 0 35,713,147 Amended related party note 0 3,997,074 Convertible notes payable 0 2,666,667 Warrants 455,514 455,514 A preferred warrant convertible into 123,077 123,077 6,153,850 6,153,850 In connection with the issuance of the Company's Series A preferred stock, warrants to purchase a total of 528,523 174,404 174,404
Fair Value	Fair Value Under U.S. GAAP, the Company is required to record certain financial assets and liabilities at fair value and may choose to record other financial assets and financial liabilities at fair value as well. Also under U.S. GAAP, the Company is required to record nonfinancial assets and liabilities at fair value due to events that may or may not recur in the future, such as an impairment event. When required to record such assets and liabilities at fair value, that fair value is estimated using an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. That fair value is determined based on significant inputs contained in a fair value hierarchy as follows: Level 1 Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three general valuation techniques that may be used to measure fair value, as described below: Market Approach Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources. Cost Approach Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Income Approach Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The following are recent accounting pronouncements that have affected our consolidated financial statements or may affect them in the future. In May 2014, the Financial Accounting Standards Board (“ Accounting Standards Update (“ Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30) Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740) as of December 31, 2015 on a prospective basis. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our December 31, 2015 consolidated balance sheet. Prior balance sheets were not retrospectively adjusted In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) statements.

SIGNIFICANT ACCOUNTING POLICI32

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule Of Useful Lives For Amortization Of Intangible Assets	Useful lives Patents and developed technologies (1) Purchased customer relationships 9 – 13 years Trademarks and trade names (2) Non-compete agreements 5 years (1) Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 5.3 (2) Trademarks and trade names of CTI are deemed to have a useful life of 15 4.3
Net Income Per Common Share	(in thousands, except shares and per share information) Year Ended December 31, 2015 2014 Numerator (in thousands): Net income (loss) $ 3,275 $ (7,716) Series A convertible preferred stock dividends (573) (509) Series C preferred stock dividends (264) (103) Series A deemed dividend 0 (2,422) Series B deemed dividend 0 (1,098) Series C deemed dividend 0 (1,401) Net income (loss) available to common stockholders – basic $ 2,438 $ (13,249) Effect of dilutive securities: Add: Convertible related party promissory note 45 0 Add: Series A convertible preferred stock dividends 573 0 Income (loss) available to common stockholders – diluted $ 3,056 $ (13,249) Denominator: Weighted average common shares outstanding – basic 21,400,244 21,294,432 Weighted average effect of dilutive common equivalent shares: Assumed conversion of Series A convertible preferred stock 37,598,865 0 Assumed conversion of Series B convertible preferred stock 35,713,147 0 Assumed conversion of Series D convertible preferred stock 4,661,221 0 Convertible related party note 2,766,876 0 Warrants 234,214 0 Options 1,478 0 Weighted average common shares outstanding – diluted 102,376,045 21,294,432 Earnings (loss) per common share: Basic $ 0.11 $ (0.62) Diluted $ 0.03 $ (0.62)
Common Shares Issuable upon Vesting or Exercise of Convertible Securities	The following potentially dilutive common share equivalents were excluded from the calculation of diluted earnings (loss) per common share because their effect was antidilutive for each of the periods presented: Year Ended December 31, 2015 2014 Options 10,505,322 10,347,322 Series A convertible preferred stock 0 33,401,765 Series B convertible preferred stock 0 35,713,147 Amended related party note 0 3,997,074 Convertible notes payable 0 2,666,667 Warrants 455,514 455,514

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	Inventories, net consist of the following (all amounts in thousands): 2015 2014 Raw materials $ 4,406 $ 4,777 Work-in-process 1,809 1,546 Finished goods 1,313 1,503 $ 7,528 $ 7,826

PREPAID EXPENSES AND OTHER CU34

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaid Expenses and Other Current Assets	2015 2014 Prepaid expenses $ 594 $ 495 Restricted cash (1) 153 0 Other current assets 50 132 $ 797 $ 627 (1) As of December 31, 2015, the Company has cash collateralizing a letter of credit for approximately $ 153,000 February 22, 2016

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following (all amounts in thousands): 2015 2014 Land $ 1,252 $ 1,267 Building and improvements 3,890 3,564 Machinery and equipment 8,877 8,408 Leasehold improvements 322 275 Furniture and fixtures 140 131 Software 132 132 14,613 13,777 Less: accumulated depreciation and amortization (7,818) (6,657) $ 6,795 $ 7,120

GOODWILL (Tables)

GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill, Impaired [Abstract]
Schedule of Goodwill	Goodwill represents the excess of the cost of acquiring CTI and CTSAS in 2008 and CSP and CTS in 2011 over the net fair value assigned to the assets acquired and liabilities assumed in those acquisitions, net of adjustments and impairment losses. Total CTI/CTSAS/CTS Consolidated Chemical Light CSP Goodwill Balance on December 31, 2013 (1) $ 5,014 $ 2,978 $ 7,992 Impairment loss (see Note 3) 0 0 0 Balance on December 31, 2014 (1) $ 5,014 $ 2,978 $ 7,992 Impairment loss (see Note 3) 0 0 0 Balance on December 31, 2015 (2) $ 5,014 $ 2,978 $ 7,992 (1)(2) Gross amount of goodwill was approximately $ 67.7 59.7

OTHER INTANGIBLE ASSETS (Tables

OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Accumulated Cost Amortization Net Book Value Developed technologies, including patents (1) $ 8,865 $ 6,903 $ 1,962 Trademarks and trade names (4) 1,070 450 620 Purchased customer relationships (2) 8,368 5,314 3,054 Non-compete agreements (3) 160 139 21 Website development costs 42 8 34 $ 18,505 $ 12,814 $ 5,691 Intangible assets as of December 31, 2014 consist of the following (all amounts in thousands): Accumulated Cost Amortization Net Book Value Developed technologies, including patents (1) $ 8,736 $ 6,582 $ 2,154 Trademarks and trade names (4) 1,068 401 667 Purchased customer relationships (2) 8,562 4,858 3,704 Non-compete agreements (3) 160 107 53 Website development costs 16 3 13 $ 18,542 $ 11,951 $ 6,591 (1) Includes a patent obtained in the acquisition of CSP with a cost of $ 50,000 17,000 5.3 (2) Includes customer relationships obtained in the acquisition of CSP with a cost of $ 920,000 60 (3) Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $ 160,000 (4) Includes CTI trademarks and trade names which were impaired by approximately $ 4.3
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The future amortization expense relating to finite-lived intangible assets for the next five years and beyond is estimated at December 31, 2015 to be (all amounts in thousands): Year Ending December 31, 2016 $ 917 2017 870 2018 870 2019 800 2020 660 Thereafter 1,574 $ 5,691

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses consist of the following (all amounts in thousands): 2015 2014 Payroll-related (1) $ 2,727 $ 834 Interest payable 9 550 Subordinated term loan exit fee 0 285 Professional fees 101 87 Franchise and sales tax payable 18 50 Other 1,003 884 $ 3,858 $ 2,690 (1) Accrued payroll-related costs as of December 31, 2015 include approximately $ 1.8 124,000 141,000

CREDIT LINE AND NOTES PAYABLE (

CREDIT LINE AND NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Outstanding notes payable consist of (all amounts in thousands): 2015 2014 Monroe Term A Loan $ 17,138 $ 0 Delayed Draw Loan 1,481 0 Senior Debt - Term Loan 0 4,239 Senior Debt - Real Estate Loan 0 1,551 Subordinated Term Loan 0 9,676 Promissory Note Payable 645 860 Total 19,264 16,326 Less: Unamortized debt discount (2,756) (337) Less: Current portion of notes payable, including current portion of unamortized debt discount (492) (5,775) Notes payable, net of current portion $ 16,016 $ 10,214
Schedule Of Carrying Value Of The Subordinated Term Loan	Interest costs during 2015 for the Monroe Term A Loan and the Delayed Draw Loan are as follows (all amounts in thousands): Term A Delayed Loan Draw Loan Contractual interest coupon rate $ 1,131 $ 64 Amortization of related debt discount and debt issuance costs 411 31 Total interest expense recognized on the Monroe debt $ 1,542 $ 95
Schedule Of Interest Costs Of The Subordinated Term Loan	As of December 31, 2015, future minimum payments due for notes payable for each of the five succeeding years and beyond are as follows (all amounts in thousands): Year Ending December 31, 2016 $ 1,078 2017 1,940 2018 2,165 2019 1,950 2020 12,131 $ 19,264

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The components of income (loss) before income taxes are as follows (all amounts in thousands): Year Ended December 31, 2015 2014 Domestic $ 2,752 $ (7,569) Foreign 732 1,091 $ 3,484 $ (6,478)
Schedule of Components of Income Tax Expense (Benefit)	Provision for income taxes consisted of the following (all amounts in thousands): Year Ended December 31, 2015 2014 Current: Federal $ (196) $ 223 State (43) 156 Foreign 310 443 Deferred: Federal (101) 2,008 State 298 (1,513) Foreign (59) (79) Provision for income taxes $ 209 $ 1,238
Schedule of Deferred Tax Assets and Liabilities	Deferred income tax assets and liabilities consist of the following (all amounts in thousands): December 31, 2015 December 31, 2014 Non-current Current Non-current Deferred tax assets: Federal $ 13,285 $ 2,699 $ 11,857 State 1,763 777 1,426 Foreign 0 0 0 Less: valuation allowance (12,243) (2,741) (10,353) 2,805 735 2,930 Deferred tax liabilities: Federal (2,385) (805) (2,103) State (616) (219) (538) Foreign (371) (16) (414) (3,372) (1,040) (3,055) Deferred tax assets (liabilities) $ (567) $ (305) $ (125) Principal components of our net liability representing deferred income tax balances are as follows (all amounts in thousands): December 31, 2015 2014 Intangible assets $ 566 $ 178 Property, plant and equipment (622) (661) U.S. loss carryforwards and tax credits, net (1) 10,004 10,151 Subsidiary income (2) (700) (764) Stock-based compensation expense 1,243 1,142 Reserves, accruals and other 430 1,664 State deferred tax asset 755 954 Valuation allowance (12,243) (13,094) $ (567) $ (430) (1) The Company had federal net operating loss carryforwards amounting to approximately $ 4.6 3.9 2027 2035 0.4 8.4 10.3 (2) A deferred tax liability has been recorded for income taxes which may become payable upon distribution of earnings of CTSAS, our French subsidiary. The estimated amount of tax that might be payable with regard to any distribution for foreign subsidiary earnings is reported net of foreign taxes paid, which are creditable against our domestic tax liability. The Company does not permanently reinvest foreign subsidiary earnings. The Company continually evaluates this assertion; if the Company’s foreign business needs change, so may this assertion.
Schedule of Effective Income Tax Rate Reconciliation	Income taxes computed using the federal statutory income tax rate differs from our effective tax rate primarily due to the following (all amounts in thousands): Year Ended December 31, 2015 2014 Provision for (benefit) from federal income taxes expected at 34% statutory rate $ 1,184 $ (2,201) Increase (reduction) resulting from: Tax on global activities, net of foreign tax credits (394) (2,842) State income taxes, less federal income tax benefit 168 (895) Loss on debt extinguishment 0 179 Change in valuation allowance (851) 7,172 Change in fair value of warrants 10 (1,518) Legal settlement (470) 0 Prior year true up 534 1,008 Other 28 335 Provision for income taxes $ 209 $ 1,238

ASSET RETIREMENT OBLIGATION (Ta

ASSET RETIREMENT OBLIGATION (Tables)	12 Months Ended
	Dec. 31, 2015
Asset Retirement Obligation Disclosure [Abstract]
Schedule Of Significant Assumptions Used To Estimate The Obligation	The Company has an obligation to remediate certain known occurrences of asbestos at our manufacturing facility in West Springfield, Massachusetts. The significant assumptions used to estimate the obligation are: Annual inflation rate 5.54 % Credit-adjusted risk-free rate 5.37 % Initial estimated remediation costs (undiscounted and not adjusted for inflation) $200,000 ($41,000 paid in 2007) Estimated remediation completion date December 19, 2038 Estimated remediation cost on December 19, 2038 $ 720,000
Schedule of Change in Asset Retirement Obligation	The following is a reconciliation of the beginning and ending aggregate carrying amounts of the asset retirement obligation (all amounts in thousands): Year Ended December 31, 2015 2014 Balance, beginning $ 204 $ 194 Accretion expense 10 10 Balance, ending $ 214 (1) $ 204 (1) The difference between the $214,000 liability as of December 31, 2015 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2015 and December 19, 2038.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under non-cancelable lease obligations at December 31, 2015 are as follows (all amounts in thousands): Year Ending December 31, 2016 $ 543 2017 279 2018 100 2019 32 2020 0 $ 954

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	2015 2014 Expected term (years) 6.0 – 6.3 6.3 – 10.0 Risk-free interest rate 1.61 – 1.74 % 1.83 – 2.31 % Estimated dividend yield None None Volatility 161.01 – 165.83 % 143.89 – 144.45 %
Schedule of Stockholders Equity Note, Warrants or Rights	Warrants to purchase the Company’s common stock were outstanding as follows as of December 31, 2015: Number of Number of Shares Shares Exercisable Under Under Exercise Expiration Warrant Holder Warrant Warrant Price Date Granite Creek FlexCap I, L.P. (“Granite”) 267,950 267,950 $ 0.01 November 19, 2023 Patriot Capital II, L.P. (“Patriot”) 187,564 187,564 $ 0.01 November 19, 2023 Dragonfly Capital Partners, LLC (“Dragonfly”) 1,003,744 1,003,744 $ 0.05 May 18, 2020
Schedule Of Change In The Fair Value Of The Warrants Liability	The change in the fair value of the warrants liability during the year ended December 31, 2015 is as follows (amounts in thousands): Granite and Patriot Warrants (see Note 11) Warrant liability at December 31, 2014 $ 25 Change in fair value of warrants 29 Warrant liability at December 31, 2015 $ 54
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Year Ended December 31, 2015 2014 Cost of revenues $ 11 $ 9 Sales and marketing 32 38 General and administrative 334 331 Research and development 27 16 $ 404 $ 394
Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity related to share-based compensation is summarized as follows: Shares Weighted Average (in thousands) Exercise Price Outstanding at December 31, 2014 2,852 $ 2.10 Granted (1) 9,197 0.09 Exercised 0 0 Forfeited/Canceled (1,520) 1.52 Expired (182) 3.04 Outstanding at December 31, 2014 10,347 0.38 Granted (2) 250 0.14 Exercised 0 0 Forfeited/Canceled (41) 0.09 Expired (1) 3.65 Outstanding at December 31, 2015 (3) 10,555 $ 0.38 Exercisable at December 31, 2015 (4) 3,853 $ 0.76 (1) The weighted-average grant-date fair value of awards granted was $ 0.09 (2) The weighted-average grant-date fair value of awards granted was $ 0.13 (3) The aggregate intrinsic value of these stock options is approximately $ 277,000 8.54 (4) The aggregate intrinsic value of these stock options is approximately $ 90,000 8.01
Schedule Of Foreign Currency Translation Adjustment In Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive loss due to currency translation adjustments (all amounts in thousands) were: Balance, December 31, 2013 $ (218) Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars (443) Balance, December 31, 2014 (661) Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars (318) Balance, December 31, 2015 $ (979)
Dragonfly Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The Dragonfly Warrant fair value of approximately $46,000 was estimated using the Black-Scholes pricing model with the following inputs: Stock price of underlying equity $ 0.05 Exercise price $ 0.05 Expected term (years) 5.0 Risk-free interest rate 1.5 % Estimated dividend yield None Volatility 157.0 %
Granite and Patriot Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value as of December 31, 2015 of the Granite and Patriot Warrants is estimated using the Black-Scholes pricing model with the following inputs: Granite and Patriot Warrants Stock price of underlying equity $ 0.12 Exercise price $ 0.01 Expected term (years) 7.9 Risk-free interest rate 2.2 % Estimated dividend yield None Volatility 167.0 %

FAIR VALUES OF ASSETS AND LIA44

FAIR VALUES OF ASSETS AND LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities itemized below were measured at fair value on a recurring basis at December 31, 2015 (all amounts in thousands): Level 1 Quoted Prices in Active Level 2 Markets Significant Level 3 Assets/ for Other Significant (Liabilities) Identical Observable Unobservable At Fair Assets Inputs Inputs Value Warrants (see Note 18) (1) $ 0 $ 0 $ (54) $ (54) $ 0 $ (0) $ (54) $ (54) (1) The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.
Reconciliation of Contingent Consideration Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The tables below presents reconciliations for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (all amounts in thousands): Year Ended December 31, 2015 2014 Warrants liability: Balance at the beginning of period $ 25 $ 6,373 Warrants amended in connection with refinancing 0 72 Warrant exercise 0 (44) Termination of common and preferred warrants 0 (1,524) Change in fair value of warrants 29 (4,852) Balance at the end of period $ 54 $ 25
Assets and Liabilities Measured at Fair Value on Non-Recurring Basis	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis During the year ended December 31, 2015, no assets were identified as impaired. During the year ended December 31, 2014, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3): Cyalume Reporting Unit (1) Loss Recognized Fair Value Patents (2) Chemical Light $ 5,277 $ 2,154 Trade name (3) Chemical Light 4,303 667 (1) The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.). (2) The fair value of the impaired patent asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach). (3) The fair value of the impaired trademarks and trade names asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).

SUPPLEMENTAL DISCLOSURE OF CA45

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Cash Paid for Interest and Income Taxes	Cash Paid for Interest and Income Taxes (all amounts in thousands): Year Ended December 31, 2015 2014 Interest $ 1,558 $ 592 Income taxes 801 244
Non-Cash Investing and Financing Activities	Non-Cash Investing and Financing Activities (all amounts in thousands): Year Ended December 31, 2015 2014 Series A Convertible Preferred stock accrued dividend $ 573 $ 509 Series C Preferred stock accrued dividend 264 103 Issuance of Series D Convertible Preferred stock in connection with debt refinancing 2,751 0 Relative fair value of warrant issued in connection with debt refinancing 43 0 Series A, Series B and Series C Preferred stock deemed dividends 0 4,921 Adjustment to warrant liability upon warrant exercise 0 44 Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP 0 241 Issuance of 242,308 shares to related party 0 157

SIGNIFICANT ACCOUNTING POLICI46

SIGNIFICANT ACCOUNTING POLICIES (Useful Lives Used For Amortization Of Intangible Assets) (Detail)	12 Months Ended
	Dec. 31, 2015
Intangible Assets Useful Life [Line Items]
Useful lives	20 years
Patented Technology [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	1 year	[1]
Customer Relationships [Member] | Minimum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	9 years
Customer Relationships [Member] | Maximum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	13 years
Trademarks and Trade Names [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	2 years	[2]
Non-compete Agreements [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	5 years
[1]	Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 years thereafter. Amortization on patent costs begins when the relevant government authority approves the related patent. Patents that have been recorded as of December 31, 2015 are expected to expire by 2034. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on patents of approximately $5.3 million was recorded during 2014 (see Note 3).
[2]	Trademarks and trade names of CTI are deemed to have a useful life of 15 years. CTI’s trademarks and trade names are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on trade names of approximately $4.3 million was recorded during 2014 (see Note 3).

SIGNIFICANT ACCOUNTING POLICI47

SIGNIFICANT ACCOUNTING POLICIES (Net Income (Loss) Per Common Share) (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Numerator (in thousands):
Net income (loss)		$ 3,275	$ (7,716)
Net income (loss) available to common stockholders - basic		2,438	(13,249)
Effect of dilutive securities:
Add: Convertible related party promissory note		45	0
Add: Series A convertible preferred stock dividends		573	0
Income (loss) available to common stockholders - diluted		$ 3,056	$ (13,249)
Denominator:
Weighted average common shares outstanding - basic		21,400,244	21,294,432
Weighted average effect of dilutive common equivalent shares:
Convertible related party note		2,766,876	0
Warrants		234,214	0
Options		1,478	0
Weighted average common shares outstanding - diluted		102,376,045	21,294,432
Earnings (loss) per common share:
Basic		$ 0.11	$ (0.62)
Diluted		$ 0.03	$ (0.62)
Series A convertible preferred stock dividends [Member]
Numerator (in thousands):
Preferred stock dividends		$ (573)	$ (509)
Series C preferred stock dividends [Member]
Numerator (in thousands):
Preferred stock dividends		(264)	(103)
Series A Deemed Dividend [Member]
Numerator (in thousands):
Preferred stock dividends		0	(2,422)
Deemed dividend		0	(2,422)
Series B Deemed Dividend [Member]
Numerator (in thousands):
Preferred stock dividends		0	(1,098)
Deemed dividend		0	(1,098)
Series C Deemed Dividend [Member]
Numerator (in thousands):
Preferred stock dividends		0	(1,401)
Deemed dividend		0	(1,401)
Series A Preferred Stock [Member]
Numerator (in thousands):
Net income (loss)		$ 0	$ 0
Preferred stock dividends	$ (2,400)
Weighted average effect of dilutive common equivalent shares:
Assumed conversion of convertible preferred stock		37,598,865	0
Series B Preferred Stock [Member]
Numerator (in thousands):
Net income (loss)		$ 0	$ 0
Weighted average effect of dilutive common equivalent shares:
Assumed conversion of convertible preferred stock		35,713,147	0
Series D Preferred Stock [Member]
Weighted average effect of dilutive common equivalent shares:
Assumed conversion of convertible preferred stock		4,661,221	0

SIGNIFICANT ACCOUNTING POLICI48

SIGNIFICANT ACCOUNTING POLICIES (Dilutive Common Share Equivalents Were Excluded From The Calculation Of Diluted Net Income Per Common Share) (Detail) - shares	1 Months Ended	12 Months Ended
	Jul. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		10,505,322	10,347,322
Series A convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,153,850	0	33,401,765
Series B convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	35,713,147
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		455,514	455,514
Warrant [Member] | Series A convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			174,404
Convertible notes payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	2,666,667
Amended related party note [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	3,997,074

SIGNIFICANT ACCOUNTING POLICI49

SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Nov. 19, 2013
Significant Accounting Policies [Line Items]
Shipping, Handling and Transportation Costs		$ 231,000	$ 358,000
Advertising Expense		$ 67,000	151,000
Finite-Lived Intangible Asset, Useful Life		20 years
Impairment Of Intangible Assets, Finite-Lived		$ 0	$ 9,580,000
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		455,514
Warrant Shares Increased	174,404
Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		455,514	455,514
Trademarks and Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Common Stock [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights			528,523
Preferred Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			6,153,850
Series A Convertible Preferred Stock [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights				123,077
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,153,850	0	33,401,765
Series A Convertible Preferred Stock [Member] | Warrant [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights	123,077
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			174,404
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		20 years
Impairment Of Intangible Assets, Finite-Lived			$ 5,300,000
Trade Names [Member]
Significant Accounting Policies [Line Items]
Impairment Of Intangible Assets, Finite-Lived			$ 4,300,000
Equipment [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		8 years
Equipment [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		4 years
Building Improvements [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		30 years

IMPAIRMENT CHARGES (Additional

IMPAIRMENT CHARGES (Additional Information) (Detail) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Dec. 13, 2015	Dec. 31, 2015	Dec. 31, 2014
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets		$ 0	$ 9,580
Chemical Light [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets	$ 9,600
Patents [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets	5,300
Trademarks and Trade Names [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets	$ 4,300

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Raw materials	$ 4,406	$ 4,777
Work-in-process	1,809	1,546
Finished goods	1,313	1,503
Inventory, Net	$ 7,528	$ 7,826

PREPAID EXPENSES AND OTHER CU52

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Schedule Of Prepaid Expenses And Other Current Assets) (Detail) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Prepaid expenses		$ 594	$ 495
Restricted cash	[1]	153	0
Other current assets		50	132
Prepaid expenses and other current assets total		$ 797	$ 627
[1]	As of December 31, 2015, the Company has cash collateralizing a letter of credit for approximately $153,000 which is used to facilitate purchases from overseas vendors. This letter of credit matures on February 22, 2016 and is included in “Prepaid expenses and other current assets” in the Company’s Consolidated Balance Sheet.

PREPAID EXPENSES AND OTHER CU53

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Additional Information) (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)
Prepaid Expenses And Other Current Assets [Line Items]
Letters Of Credit Carrying Value	$ 153,000
Letters Of Credit Expiration Date	Feb. 22, 2016

PROPERTY, PLANT AND EQUIPMENT54

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Land	$ 1,252	$ 1,267
Building and improvements	3,890	3,564
Machinery and equipment	8,877	8,408
Leasehold improvements	322	275
Furniture and fixtures	140	131
Software	132	132
Property, Plant and Equipment, Gross	14,613	13,777
Less: accumulated depreciation and amortization	(7,818)	(6,657)
Property, Plant and Equipment, Net	$ 6,795	$ 7,120

GOODWILL (Schedule Of Goodwill,

GOODWILL (Schedule Of Goodwill, Impairment Loss) (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2013
Goodwill [Line Items]
Beginning balance	[1]	$ 7,992
Impairment loss (see Note 3)		0	$ 0
Ending balance	[1]	7,992	7,992
CSP [Member]
Goodwill [Line Items]
Beginning balance	[1]	2,978
Impairment loss (see Note 3)		0	0
Ending balance	[1]	2,978	2,978
Chemical Light [Member]
Goodwill [Line Items]
Beginning balance	[1]	5,014
Impairment loss (see Note 3)		0	0
Ending balance	[1]	$ 5,014	$ 5,014
[1]	Gross amount of goodwill was approximately $67.7 million as of December 31, 2015 and 2014. Accumulated impairment losses incurred prior to 2015 were approximately $59.7 million as of December 31, 2015 and 2014.

GOODWILL (Additional Informatio

GOODWILL (Additional Information) (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Goodwill, Gross	$ 67,700	$ 67,700
Goodwill, Impaired, Accumulated Impairment Loss	$ 59,700	$ 59,700

OTHER INTANGIBLE ASSETS (Schedu

OTHER INTANGIBLE ASSETS (Schedule Of Showing Of Components Of Other Intangible Assets) (Detail) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Cost		$ 18,505	$ 18,542
Accumulated Amortization		12,814	11,951
Net Book Value		5,691	6,591
Developed Technologies Including Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[1]	8,865	8,736
Accumulated Amortization	[1]	6,903	6,582
Net Book Value	[1]	1,962	2,154
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[2]	1,070	1,068
Accumulated Amortization	[2]	450	401
Net Book Value	[2]	620	667
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[3]	8,368	8,562
Accumulated Amortization	[3]	5,314	4,858
Net Book Value	[3]	3,054	3,704
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[4]	160	160
Accumulated Amortization	[4]	139	107
Net Book Value	[4]	21	53
Website Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Cost		42	16
Accumulated Amortization		8	3
Net Book Value		$ 34	$ 13
[1]	Includes a patent obtained in the acquisition of CSP with a cost of $50,000 that is expected to be fully amortized in August 2026 and also includes $17,000 of CTS patents which were transferred to CTI in 2014. The CTI patents were impaired by approximately $5.3 million during 2014 (see Note 3 Impairment Charges).
[2]	Includes CTI trademarks and trade names which were impaired by approximately $4.3 million during 2014 (see Note 3 Impairment Charges).
[3]	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. The $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.
[4]	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016.

OTHER INTANGIBLE ASSETS (Future

OTHER INTANGIBLE ASSETS (Future Amortization Expense Related To Other Intangible Assets) (Detail) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 917
2,017	870
2,018	870
2,019	800
2,020	660
Thereafter	1,574
Total future amortization expense	$ 5,691

OTHER INTANGIBLE ASSETS (Additi

OTHER INTANGIBLE ASSETS (Additional Information) (Detail) - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill), Total		$ 5,691,000	$ 6,591,000
Finite Lived Intangible Assets Cost Incurred To Create Or Defend		$ 2,000	5,000
Useful lives		20 years
Amortization Of Intangible Assets		$ 954,000	1,812,000
Impairment Of Intangible Assets, Finite-Lived		0	9,580,000
Trademarks [Member]
Other Intangible Assets [Line Items]
Impairment Of Intangible Assets, Finite-Lived			4,300,000
Patents [Member]
Other Intangible Assets [Line Items]
Finite Lived Intangible Assets Cost Incurred To Create Or Defend		$ 130,000	160,000
Useful lives		20 years
Impairment Of Intangible Assets, Finite-Lived			5,300,000
Noncompete Agreements [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill), Total	[1]	$ 21,000	53,000
Useful lives		5 years
Customer Relationships [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill), Total	[2]	$ 3,054,000	3,704,000
Cyalume Specialty Products Inc [Member] | Patents [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			50,000
Cyalume Specialty Products Inc [Member] | Noncompete Agreements [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		160,000
Cyalume Specialty Products Inc [Member] | Customer Relationships [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 920,000
Combat Training Solutions Inc [Member] | Patents [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			17,000
Combat Training Solutions Inc [Member] | Customer Relationships [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill), Total			$ 60,000
[1]	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016.
[2]	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. The $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.

DEBT ISSUANCE COSTS (Additional

DEBT ISSUANCE COSTS (Additional Information) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Amortization of Financing Costs	$ 240,000	$ 42,000
Interest Expense [Member]
Amortization of Financing Costs	$ 1,600,000

ACCRUED EXPENSES (Schedule Of A

ACCRUED EXPENSES (Schedule Of Accrued Expenses) (Detail) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Payroll-related	[1]	$ 2,727	$ 834
Interest payable		9	550
Subordinated term loan exit fee		0	285
Professional fees		101	87
Franchise and sales tax payable		18	50
Other		1,003	884
Accounts Payable and Accrued Liabilities		$ 3,858	$ 2,690
[1]	Accrued payroll-related costs as of December 31, 2015 include approximately $1.8 million of accrued bonus costs and approximately $124,000 of accrued severance costs. Accrued payroll-related costs as of December 31, 2014 include approximately $141,000 of accrued severance costs.

ACCRUED EXPENSES (Additional In

ACCRUED EXPENSES (Additional Information) (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Accrued Bonuses	$ 1,800,000
Employee Severance [Member]
Accrued Expenses [Line Items]
Payroll-related	$ 124,000	$ 141,000

CREDIT LINE AND NOTES PAYABLE63

CREDIT LINE AND NOTES PAYABLE (Outstanding Notes Payable) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Promissory Note Payable	$ 645	$ 860
Total	19,264	16,326
Less: Unamortized debt discount	(2,756)	(337)
Less: Current portion of notes payable, including current portion of unamortized debt discount	(492)	(5,775)
Notes payable, net of current portion	16,016	10,214
Monroe Term A Loan [Member]
Bank Loans	17,138	0
Delayed Draw Loan [Member]
Bank Loans	1,481	0
TD Bank Term Loan [Member]
Bank Loans	0	4,239
TD Bank Real Estate Loan [Member]
Bank Loans	0	1,551
Subordinated Term [Member]
Bank Loans	$ 0	$ 9,676

NOTES PAYABLE (Interest Costs F

NOTES PAYABLE (Interest Costs For The Subordinated Term Loan) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Monroe Loan [Member]
Schedule Of Subordinated Term Loan [Line Items]
Contractual interest coupon rate	$ 1,131
Amortization of related debt discount and debt issuance costs	411
Total interest expense recognized on the Monroe debt	1,542
Delayed Draw Loan [Member]
Schedule Of Subordinated Term Loan [Line Items]
Contractual interest coupon rate	64
Amortization of related debt discount and debt issuance costs	31
Total interest expense recognized on the Monroe debt	$ 95

NOTES PAYABLE (Future Minimum P

NOTES PAYABLE (Future Minimum Payments Due For Notes Payable) (Detail) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 1,078
2,017	1,940
2,018	2,165
2,019	1,950
2,020	12,131
Long-term Debt	$ 19,264

CREDIT LINE AND NOTES PAYABLE66

CREDIT LINE AND NOTES PAYABLE (Additional Information) (Detail)	Aug. 03, 2015USD ($)	May. 18, 2015USD ($)shares	Dec. 31, 2013$ / sharesshares	Nov. 19, 2013USD ($)	Jul. 29, 2010USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2015EUR (€)shares	Dec. 31, 2010$ / sharesshares
Notes Payable [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						455,514		455,514
Proceeds from Issuance of Debt						$ 8,500,000
Amortization of Debt Discount (Premium)						661,000	$ 205,000
Line of Credit Facility, Maximum Borrowing Capacity						820,000		€ 750,000
Line of Credit, Current						1,000,000	2,050,000
Amortization Of Financing Costs						240,000	$ 42,000
Term A Loan And Delayed Draw Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Unamortized Discount						$ 2,400,000
Delayed Draw Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Effective Percentage						20.00%		20.00%
Series D Convertible Preferred Stock [Member]
Notes Payable [Line Items]
Preferred Stock Shares Issued | shares						10	10	10
Long-term Debt, Fair Value						$ 2,800,000
Debt Instrument, Unamortized Discount						$ 400,000
Monroe Credit Agreement [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date		Jun. 30, 2017
Debt Instrument, Periodic Payment	$ 1,400,000	$ 11,300,000
Debt Instrument, Face Amount		$ 25,000,000
Line of Credit Facility, Interest Rate Description		interest at a rate of the one-month LIBOR plus 9%
Debt Instrument, Term		5 years
Line of Credit Facility, Covenant Terms						a fixed charge coverage ratio of 1.25 to 1.00; (ii) a senior debt to EBITDA ratio of 4.50 to 1.00, decreasing to 1.50 to 1.00 over the term of the loans; and (iii) a twelve month trailing EBITDA, measured quarterly, in the amount of $4,750,000, increasing to $7.0 million over the term of the loans
Line of Credit Facility, Frequency of Payment and Payment Terms						quarterly amortization payments on the last day of each calendar quarter in an aggregate principal amount equal to 0.625% of the original principal amount of the Delayed Draw Loan, increasing to 1.25% on March 31, 2016, and increasing to 2.5% on March 31, 2017, with the balance payable on the maturity date of May 18, 2020.
Line of Credit Facility, Description						$5.0 million and (ii) the sum of 85% of all eligible accounts receivable plus 60% of all eligible inventory.
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	1,500,000
Debt Issuance Cost	100,000
Debt Instrument, Annual Principal Payment	$ 2,000,000
Monroe Credit Agreement [Member] | Series D Preferred Stock [Member]
Notes Payable [Line Items]
Preferred Stock Shares Issued | shares		10
Monroe Credit Agreement [Member] | Series D Convertible Preferred Stock [Member]
Notes Payable [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion | shares		752,807.8
Monroe Credit Agreement [Member] | Quarterly Repayments Beginning on June 30, 2015 through March 31, 2016 [Member]
Notes Payable [Line Items]
Debt Instrument, Periodic Payment		$ 113,000
Monroe Credit Agreement [Member] | Quarterly Repayments Beginning On June 30, 2016 Through March 31, 2017 [Member]
Notes Payable [Line Items]
Debt Instrument, Periodic Payment		225,000
Monroe Credit Agreement [Member] | Quarterly Repayments Of Beginning on June 30, 2017 through March 31, 2020 [Member]
Notes Payable [Line Items]
Debt Instrument, Periodic Payment		450,000
Monroe Credit Agreement [Member] | Revolving Credit Facility [Member]
Notes Payable [Line Items]
Debt Instrument, Face Amount		5,000,000
Monroe Credit Agreement [Member] | Secured Debt [Member]
Notes Payable [Line Items]
Debt Instrument, Face Amount		18,000,000
Monroe Credit Agreement [Member] | Legal Reserve Delayed Draw Term Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Face Amount		$ 2,000,000
TD Bank [Member]
Notes Payable [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 5,000,000
Line of Credit Facility, Interest Rate During Period						10.00%
Line of Credit, Current						$ 1,000,000
Line of Credit Facility, Remaining Borrowing Capacity						$ 4,000,000
Promissory Notes Payable [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				2.00%
Debt Instrument, Maturity Date				Oct. 15, 2018
Debt Instrument, Periodic Payment				$ 215,000
Debt Instrument, Face Amount				$ 1,075,000
Before Amendment [Member] | Monroe Credit Agreement [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date		Mar. 31, 2020
Maximum [Member] | Monroe Credit Agreement [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date						May 18, 2020
Subordinated Term Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date		Mar. 31, 2017	Jun. 30, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			455,514						160,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.01						$ 1.50
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 54,000
Term Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date		Jun. 30, 2016
Debt Instrument, Interest Rate, Effective Percentage						17.00%		17.00%
Term Loan [Member] | Maximum [Member]
Notes Payable [Line Items]
Debt Instrument, Maturity Date		May 18, 2020
Granite Creek Partners Agent Llc [Member]
Notes Payable [Line Items]
Subordinated Borrowing, Interest Rate					11.00%
Debt Instrument, Maturity Date					Jun. 30, 2016
Debt Instrument Convertible Number Of Equity Instrument | shares					2,666,667
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 3.19
Issuance Of Loan					$ 8,500,000

RELATED PARTY TRANSACTIONS (Add

RELATED PARTY TRANSACTIONS (Additional Information) (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May. 18, 2015	Dec. 31, 2015	Dec. 31, 2014	Jul. 30, 2014	Nov. 19, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Unsecured Debt			$ 2,100,000
Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock Par Or Stated Value Per Share				$ 0.001
Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock Par Or Stated Value Per Share		$ 0.001	$ 0.001	$ 0.001
Jfc [Member]
Related Party Transaction [Line Items]
Unsecured Debt						$ 2,100,000
Amended JFC Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					12.00%
Debt Instrument, Convertible, Conversion Price					$ 32.50
Convertible Debt					$ 1,000,000
Repayments of Related Party Debt	$ 2,100,000
Repayments Of Related Party Debt, Accrued interest	500,000
James Schleck [Member] | Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 650
Debt Conversion, Converted Instrument, Shares Issued	20
Cyalume Specialty Products Inc [Member]
Related Party Transaction [Line Items]
Monthly Lease Payments Due To Related Parties		$ 30,000
Lease Expiration Date		Aug. 31, 2016

INCOME TAXES (The Components of

INCOME TAXES (The Components of Income (Loss) Before Income Taxes) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Domestic	$ 2,752	$ (7,569)
Foreign	732	1,091
Loss before income taxes	$ 3,484	$ (6,478)

INCOME TAXES (Benefit From Inco

INCOME TAXES (Benefit From Income Taxes Consisted) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal	$ (196)	$ 223
State	(43)	156
Foreign	310	443
Deferred:
Federal	(101)	2,008
State	298	(1,513)
Foreign	(59)	(79)
Provision for income taxes	$ 209	$ 1,238

INCOME TAXES (The Consist of De

INCOME TAXES (The Consist of Deferred Income Tax Assets And Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current		$ 735
Deferred tax assets, Non-current	$ 2,805	2,930
Deferred tax liabilities, Current		(305)
Deferred tax liabilities, Non-current	(567)	(125)
Federal [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current		2,699
Deferred tax assets, Non-current	13,285	11,857
Deferred tax liabilities, Current		(805)
Deferred tax liabilities, Non-current	(2,385)	(2,103)
State [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current		777
Deferred tax assets, Non-current	1,763	1,426
Deferred tax liabilities, Current		(219)
Deferred tax liabilities, Non-current	(616)	(538)
Foreign [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current		0
Deferred tax assets, Non-current	0	0
Deferred tax liabilities, Current		(16)
Deferred tax liabilities, Non-current	(371)	(414)
valuation allowance
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Valuation allowance, Current		(2,741)
Valuation allowance, Non-current	(12,243)	(10,353)
Deferred tax liabilities, Current		(1,040)
Deferred tax liabilities, Non-current	$ (3,372)	$ (3,055)

INCOME TAXES (Principal Compone

INCOME TAXES (Principal Components Of Our Net Liability Representing Deferred Income Tax Balances) (Detail) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Intangible assets		$ 566	$ 178
Property, plant and equipment		(622)	(661)
U.S. loss carryforwards and tax credits, net	[1]	10,004	10,151
Subsidiary income		(700)	(764)
Stock-based compensation expense		1,243	1,142
Reserves, accruals and other		430	1,664
State deferred tax asset		755	954
Valuation allowance		(12,243)	(13,094)
Deferred Tax Assets, Net, Total		$ (567)	$ (430)
[1]	The Company had federal net operating loss carryforwards amounting to approximately $4.6 million and $3.9 million at December 31, 2015 and 2014, respectively. The net operating loss carryforward at December 31, 2015 expires in fiscal years 2027 through 2035. Internal Revenue Code Section 382 limits utilization of these losses to approximately $0.4 million per year. It is possible that future changes in ownership could result in changes to the amounts allowed by IRC Section 382. State net operating loss carryforwards amounted to approximately $8.4 million and $10.3 million as of December 31, 2015 and 2014, respectively.

INCOME TAXES (Principal Compo72

INCOME TAXES (Principal Components Of Our Net Liability Representing Deferred Income Tax Balances) (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 4.6	$ 3.9
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	8.4	$ 10.3
Limitations On Use Operating Loss Carryforwards	$ 0.4
Maximum [Member]
Operating Loss Carryforwards Expiration Year	2,035
Minimum [Member]
Operating Loss Carryforwards Expiration Year	2,027

INCOME TAXES (The Federal Statu

INCOME TAXES (The Federal Statutory Income Tax Rate Differs From Our Effective Tax Rate) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Provision for (benefit) from federal income taxes expected at 34% statutory rate	$ 1,184	$ (2,201)
Increase (reduction) resulting from:
Tax on global activities, net of foreign tax credits	(394)	(2,842)
State income taxes, less federal income tax benefit	168	(895)
Loss on debt extinguishment	0	179
Change in valuation allowance	(851)	7,172
Change in fair value of warrants	10	(1,518)
Legal settlement	(470)	0
Prior year true up	534	1,008
Other	28	335
Provision for income taxes	$ 209	$ 1,238

INCOME TAXES (The Federal Sta74

INCOME TAXES (The Federal Statutory Income Tax Rate Differs From Our Effective Tax Rate) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%

ASSET RETIREMENT OBLIGATION (Th

ASSET RETIREMENT OBLIGATION (The Significant Assumptions Used To Estimate The Obligation) (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)
Asset Retirement Obligation Disclosure [Line Items]
Annual inflation rate	5.54%
Credit-adjusted risk-free rate	5.37%
Initial estimated remediation costs (undiscounted and not adjusted for inflation)	$ 200,000
Estimated remediation completion date	Dec. 19, 2038
Estimated remediation cost on December 19, 2038	$ 720,000

ASSET RETIREMENT OBLIGATION (76

ASSET RETIREMENT OBLIGATION (The Significant Assumptions Used To Estimate The Obligation) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2007USD ($)
Asset Retirement Obligation Disclosure [Line Items]
Undiscounted and not adjusted for inflation	$ 41,000

ASSET RETIREMENT OBLIGATION (Re

ASSET RETIREMENT OBLIGATION (Reconciliation of The Beginning And Ending Aggregate Carrying Amounts Of The Asset Retirement Obligation) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015		Dec. 31, 2014
Asset Retirement Obligation Disclosure [Line Items]
Balance, beginning	$ 204		$ 194
Accretion expense	10		10
Balance, ending	$ 214	[1]	$ 204
[1]	The difference between the $214,000 liability as of December 31, 2015 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2015 and December 19, 2038.

COMMITMENTS AND CONTINGENCIES78

COMMITMENTS AND CONTINGENCIES (Future Minimum Lease Payments) (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Line Items]
2,016	$ 543
2,017	279
2,018	100
2,019	32
2,020	0
Operating Leases, Future Minimum Payments Due	$ 954

COMMITMENTS AND CONTINGENCIES79

COMMITMENTS AND CONTINGENCIES (Additional Information) (Detail) - USD ($)	1 Months Ended			12 Months Ended
	Nov. 20, 2013	Nov. 19, 2013	Jul. 18, 2011	Dec. 31, 2015	Dec. 31, 2014	Oct. 10, 2016	Aug. 31, 2016	Jan. 10, 2016	Dec. 31, 2013
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Awarded, Value			$ 235,000
Loss Contingency, Settlement Agreement, Terms				Pursuant to the Omniglow Settlement Agreement, CTI agreed to either pay the full settlement amount of approximately $4.5 million or satisfy the settlement amount as follows: (i) an initial payment of $250,000, (ii) transfer the 625,139 Escrowed Shares, (iii) payment of $1.0 million in cash within 21 days from the execution of the Omniglow Settlement Agreement and (iv) additional payments in cash and/or through cooperative marketing credits of $1.9 million if paid within 18 months from the date of the Omniglow Settlement Agreement, or of approximately $2.4 million if paid within 27 months from the date of the Omniglow Settlement Agreement.
Payments for Legal Settlements				$ 215,000	$ 215,000
Escrow Shares Fair Value		625,139							625,139
Scenario, Forecast [Member]
Commitments and Contingencies Disclosure [Line Items]
Future Minimum Lease Payments, Required Per Month							$ 24,000
Subsequent Event [Member]
Commitments and Contingencies Disclosure [Line Items]
Election payment						$ 2,350,000
Reduced Final Payment in Lieu of a Payment								$ 1,900,000
Promissory Note [Member]
Commitments and Contingencies Disclosure [Line Items]
Repayments of Debt				215,000	215,000
Mr.Colon [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Amount		$ 215,000
Payments for Legal Settlements	$ 275,000
Mr.Colon [Member] | Promissory Note [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Amount		$ 1,075,000
CTI [Member]
Commitments and Contingencies Disclosure [Line Items]
Reduced Final Payment				1,400,000
Omniglow [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Awarded, Value			$ 2,600,000
Prejudgment Interest Rate			12.00%
Loss contingency damages awarded accrued interest			$ 1,300,000
Omniglow [Member] | Attorney Fees and Costs [Member]
Commitments and Contingencies Disclosure [Line Items]
Prejudgment Interest Rate			12.00%
Newmark Knight and Frank [Member]
Commitments and Contingencies Disclosure [Line Items]
Future Minimum Lease Payments, Required Per Month				30,000
Operating Leases [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense				$ 725,000	$ 756,000

PREFERRED STOCK (Additional Inf

PREFERRED STOCK (Additional Information) (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 30, 2014	Nov. 19, 2013	Dec. 31, 2015	Dec. 31, 2014
Preferred Stock Disclosure [Line Items]
Preferred Stock Fair Value Estimated	$ 1,600
Proceeds from Issuance of Preferred Stock and Preference Stock	2,000		$ 0	$ 2,000
Series A Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Liquidation Preference Per Share			$ 32.50
Convertible Preferred Stock, Shares Issued upon Conversion			50
Convertible Preferred Stock Conversion Price			$ 0.65
Conversion Price			$ 0.13664587
Preferred Stock Dividends, Income Statement Impact	$ 2,400
Series A Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Preferred Stock Par Or Stated Value Per Share			$ 0.001	$ 0.001
Preferred Stock, Dividend Rate, Percentage			12.00%
Preferred Stock Dividends, Income Statement Impact			$ 573	$ 509
Preferred Stock Shares Issued			123,097	123,077
Series A Convertible Preferred Stock [Member] | Minimum [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Liquidation Preference Per Share			$ 3,000
Series C Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Stock Issued During Period, Value, Other				$ 0
Preferred Stock Par Or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Preferred Stock, Dividend Rate, Percentage			12.00%
Preferred Stock Dividends, Income Statement Impact			$ 264	$ 103
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,400
Preferred Stock Dividend Payable Percentage Of Shares			75.00%
Accrued Dividends Payable In Cash Or In Kind Per Share			$ 2,000
Preferred Stock Shares Issued			1,000	1,000
Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Preferred Stock Par Or Stated Value Per Share			$ 0.001	$ 0.001
Conversion of Stock, Shares Converted	35,713.147
Preferred Stock Shares Issued			1,000	1,000
Series B Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock Par Or Stated Value Per Share	$ 0.001
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,400
Convertible To Common Stock Fair Value	2,500
Preferred Stock Beneficial Conversion Feature	1,100
Series B And C Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	600
Series C Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	600
Series D Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Stock Issued During Period, Value, Other				$ 0
Preferred Stock Par Or Stated Value Per Share			$ 0.001	$ 0.001
Proceeds from Issuance of Preferred Stock and Preference Stock			$ 2,800
Conversion of Stock, Shares Converted			752,807.8
Preferred Stock Shares Issued			10	10
Purchase Agreement [Member]
Preferred Stock Disclosure [Line Items]
Stock Issued During Period, Value, Other	$ 2,000
Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock Par Or Stated Value Per Share		$ 0.001
Purchase Agreement [Member] | Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Conversion Basis	if the Company issues or sells shares of Common Stock or other equity securities for no consideration or for consideration that is based on an equity valuation of the Company of less than $2.0 million in the aggregate (a Trigger Issuance). In the event of a Trigger Issuance, the Conversion Number shall be increased as of the close of business on the effective date of the Trigger Issuance to a number calculated as follows: (i) two-thirds of the Common Stock deemed Outstanding (as defined in the Amended Series A Certificate of Designation) immediately following such Trigger Issuance (excluding any Common Stock Deemed Outstanding as a result of the conversion of the Series B Preferred Stock) (ii) divided by 1,000. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on the tenth anniversary of its original issuance date, at the then-current Conversion Number.
Series A Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Stock Issued During Period, Shares, Other		123,077
Stock Issued During Period, Value, Other		$ 4,000
Sale of Stock, Price Per Share		$ 32.50
Series B and C Purchase Agreement [Member] | Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Stock Issued During Period, Shares, Other	1,000
Stock Issued During Period, Value, Other	$ 2,000
Sale of Stock, Price Per Share	$ 2,000
Preferred Stock Par Or Stated Value Per Share	$ 0.001
Net Proceeds from Sale of Preferred Units Used to Pay Contingent Legal Obligation	$ 1,300
Series B and C Purchase Agreement [Member] | Series C Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock Par Or Stated Value Per Share	$ 0.001

STOCKHOLDERS' EQUITY (The Drago

STOCKHOLDERS' EQUITY (The Dragonfly Warrant fair value is estimated using the Black-Scholes pricing model) (Detail) - Dragonfly Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price of underlying equity	$ 0.05
Exercise price	$ 0.05
Expected term (years)	5 years
Risk-free interest rate	1.50%
Estimated dividend yield	0.00%
Volatility	157.00%

STOCKHOLDERS' EQUITY (Warrants

STOCKHOLDERS' EQUITY (Warrants To Purchase Common Stock Outstanding) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	May. 18, 2015
Class of Warrant or Right [Line Items]
Number of Shares Exercisable Under Warrant	455,514
Granite Creek FlexCap I, L.P [Member]
Class of Warrant or Right [Line Items]
Number of Shares Under Warrant	267,950
Number of Shares Exercisable Under Warrant	267,950
Exercise Price	$ 0.01
Expiration Date	Nov. 19, 2023
Patriot Capital II, L.P [Member]
Class of Warrant or Right [Line Items]
Number of Shares Under Warrant	187,564
Number of Shares Exercisable Under Warrant	187,564
Exercise Price	$ 0.01
Expiration Date	Nov. 19, 2023
Dragonfly Capital Partners, LLC [Member]
Class of Warrant or Right [Line Items]
Number of Shares Under Warrant	1,003,744
Number of Shares Exercisable Under Warrant	1,003,744	1,003,744
Exercise Price	$ 0.05	$ 0.05
Expiration Date	May 18, 2020

STOCKHOLDERS' EQUITY (Granite a

STOCKHOLDERS' EQUITY (Granite and Patriot Warrants is estimated using the Black-Scholes pricing model) (Detail) - Granite and Patriot Warrants [Member]	12 Months Ended
	Dec. 31, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price of underlying equity	$ 0.12
Exercise price	$ 0.01
Expected term (years)	7 years 10 months 24 days
Risk-free interest rate	2.20%
Estimated dividend yield	0.00%
Volatility	167.00%

STOCKHOLDERS' EQUITY (Change In

STOCKHOLDERS' EQUITY (Change In The Fair Value Of The Warrants Liability) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Change in fair value of warrants	$ 29	$ (4,852)
Granite and Patriot Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2014	25
Change in fair value of warrants	29
Warrant liability at December 31, 2015	$ 54	$ 25

STOCKHOLDERS' EQUITY (Share-Bas

STOCKHOLDERS' EQUITY (Share-Based Expenses Are Included In Our Consolidated Statements Of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 404	$ 394
Cost of revenues [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	11	9
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	32	38
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	334	331
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 27	$ 16

STOCKHOLDERS' EQUITY (The Black

STOCKHOLDERS' EQUITY (The Black-Scholes Pricing Model With The Following Assumptions For Awards To Employees And Non-Employees) (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (Minimum)	1.61%	1.83%
Risk-free interest rate (Maximum)	1.74%	2.31%
Estimated dividend yield	0.00%	0.00%
Volatility (Minimum)	161.01%	143.89%
Volatility (Maximum)	165.83%	144.45%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 months 18 days	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years	6 years 3 months 18 days

STOCKHOLDERS' EQUITY (Stock Opt

STOCKHOLDERS' EQUITY (Stock Option Activity Related To Share-Based Compensation) (Detail) - $ / shares shares in Thousands		12 Months Ended
		Dec. 31, 2015		Dec. 31, 2014
Outstanding Shares, Beginning		10,347		2,852
Shares Granted		250	[1]	9,197	[2]
Shares Exercised		0		0
Shares Forfeited/Canceled		(41)		(1,520)
Shares Expired		(1)		(182)
Outstanding Shares, Ending		10,555	[3]	10,347
Shares Exercisable	[4]	3,853
Outstanding Weighted Average Exercise Price, Beginning		$ 0.38		$ 2.10
Weighted Average Exercise Price Granted		0.14	[1]	0.09	[2]
Weighted Average Exercise Price Exercised		0		0
Weighted Average Exercise Price Forfeited/Canceled		0.09		1.52
Weighted Average Exercise Price Expired		3.65		3.04
Outstanding Weighted Average Exercise Price, Ending		0.38	[3]	$ 0.38
Weighted Average Exercise Price Exercisable	[4]	$ 0.76
[1]	The weighted-average grant-date fair value of awards granted was $0.13.
[2]	The weighted-average grant-date fair value of awards granted was $0.09.
[3]	The aggregate intrinsic value of these stock options is approximately $277,000 as of December 31, 2015. The weighted average remaining contractual term for these options is 8.54 years.
[4]	The aggregate intrinsic value of these stock options is approximately $90,000 as of December 31, 2015. The weighted average remaining contractual term for these options is 8.01 years.

STOCKHOLDERS' EQUITY (Changes I

STOCKHOLDERS' EQUITY (Changes In Accumulated Other Comprehensive Loss Due To Currency Translation Adjustments) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Beginning balance	$ (661)	$ (218)
Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars	(318)	(443)
Ending balance	$ (979)	$ (661)

STOCKHOLDERS' EQUITY (Additiona

STOCKHOLDERS' EQUITY (Additional Information) (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May. 18, 2015	Dec. 31, 2015		Dec. 31, 2014		Nov. 21, 2014	Dec. 31, 2012
Stockholders Equity Additional Information [Line Items]
Common stock, shares authorized		150,000,000		150,000,000
Stock-based compensation expense		$ 404,000		$ 394,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 502,000				$ 400,000
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		455,514
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		250,000	[1]	9,197,000	[2]
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price		$ 0.14	[1]	$ 0.09	[2]
Fair Value Adjustment of Warrants		$ 29,000		$ (4,852,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		277,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 90,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		8 years 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		8 years 6 months 14 days
Dragonfly Warrant [Member]
Stockholders Equity Additional Information [Line Items]
Fair Value Adjustment of Warrants		$ 46,000
Dragonfly Capital Partners, LLC [Member]
Stockholders Equity Additional Information [Line Items]
Debt Issuance Cost	$ 820,000
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights	1,003,744	1,003,744
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.05	$ 0.05
Monroe Warrant [Member] | Dragonfly Warrant [Member]
Stockholders Equity Additional Information [Line Items]
Fair Value Adjustment of Warrants		$ 43,000
Chief Operating Officer [Member]
Stockholders Equity Additional Information [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		1,504,767
Chief Executive Officer [Member]
Stockholders Equity Additional Information [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		5,015,891
Maximum [Member]
Stockholders Equity Additional Information [Line Items]
Stock Options Awarded Vest Period		5 years
Minimum [Member]
Stockholders Equity Additional Information [Line Items]
Stock Options Awarded Vest Period		0 years
2014 Equity Incentive Plan
Stockholders Equity Additional Information [Line Items]
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price		$ 0.09
Unrestricted Stock Awards [Member] | 2009 Equity Incentive Plan
Stockholders Equity Additional Information [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		2,650,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,149,082
Unrestricted Stock Awards [Member] | 2014 Equity Incentive Plan
Stockholders Equity Additional Information [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,885,582
Stock Option And Warrant Awards [Member]
Stockholders Equity Additional Information [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		2 years 8 months 1 day
Subordinated Term Loan [Member]
Stockholders Equity Additional Information [Line Items]
Class of Warrant or Right, Outstanding							160,000
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		455,514		455,514
[1]	The weighted-average grant-date fair value of awards granted was $0.13.
[2]	The weighted-average grant-date fair value of awards granted was $0.09.

EMPLOYEE BENEFIT PLANS (Additio

EMPLOYEE BENEFIT PLANS (Additional Information) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	The CTI Employee Savings and Retirement Plan (the ESRP), is intended to be qualified under Section 401(k) of the Internal Revenue Code. Employees of CTI, CTS and CSP who have reached the age of 18 are eligible for participation on the first entry date after three months of service. Entry dates are the first day of January, April, July and October. Employees may defer receiving compensation up to the maximum amount permitted under the Internal Revenue Code. Matching contributions to the ESRP equal (i) 3% of employee compensation plus (ii) 50% of the next 2% of employee compensation. For the years ended December 31, 2015 and 2014, employer matching contributions were approximately $211,000 and $58,000, respectively.
Defined Contribution Plan Employer Matching Contribution Annual Amount	$ 211,000	$ 58,000
Defined Benefit Plan, Benefit Obligation	$ 81,000	$ 78,000

CONCENTRATIONS (Additional Info

CONCENTRATIONS (Additional Information) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]
Insurance Coverage			$ 250,000
Cash, Uninsured Amount	$ 600,000
Insurance Coverage Exceed Limits	$ 600,000
Outside United States Customer [Member] | Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	31.00%	52.00%
CTSAS [Member]
Concentration Risk [Line Items]
Assets, Net	$ 2,853,000	$ 3,362,000
United Kingdom [Member] | Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	7.00%	12.00%
Three Customers [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	53.00%	49.00%
Two Customers [Member] | Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	37.00%	41.00%
Other Customer [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%

FAIR VALUES OF ASSETS AND LIA92

FAIR VALUES OF ASSETS AND LIABILITIES (Assets And Liabilities Measured At Fair Value On Recurring Basis) (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	$ (54)
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	(54)	[1]
Level 1 Quoted Prices in Active Markets for Identical Assets [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0
Level 1 Quoted Prices in Active Markets for Identical Assets [Member] | Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]
Level 2 Significant Other Observable Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0
Level 2 Significant Other Observable Inputs [Member] | Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]
Level 3 Significant Unobservable Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	(54)
Level 3 Significant Unobservable Inputs [Member] | Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	$ (54)	[1]
[1]	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.

FAIR VALUES OF ASSETS AND LIA93

FAIR VALUES OF ASSETS AND LIABILITIES (Consideration Liability Measured at Fair Value on Recurring Basis) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Termination of common and preferred warrants		$ 1,525
Balance at the end of period	$ 54
Warrants Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period	25	6,373
Warrants amended in connection with refinancing	0	72
Warrant exercise	0	(44)
Termination of common and preferred warrants	0	(1,524)
Change in fair value of warrants	29	(4,852)
Balance at the end of period	$ 54	$ 25

FAIR VALUES OF ASSETS AND LIA94

FAIR VALUES OF ASSETS AND LIABILITIES (Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Patents [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit	Chemical Light	[1],[2]
Loss Recognized	$ 5,277	[2]
Fair Value	$ 2,154	[2]
Trade Name [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit	Chemical Light	[1],[3]
Loss Recognized	$ 4,303	[3]
Fair Value	$ 667	[3]
[1]	The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.).
[2]	The fair value of the impaired patent asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach).
[3]	The fair value of the impaired trademarks and trade names asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).

SUPPLEMENTAL DISCLOSURE OF CA95

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Cash Paid for Interest and Income Taxes) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Interest	$ 1,558	$ 592
Income taxes	$ 801	$ 244

SUPPLEMENTAL DISCLOSURE OF CA96

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Non-Cash Investing and Financing Activities) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Non-Cash Investing And Financing Activities [Line Items]
Series A, Series B and Series C Preferred stock deemed dividends	$ 0	$ 4,921
Relative fair value of warrant issued in connection with debt refinancing	43	0
Adjustment to warrant liability upon warrant exercise	0	44
Selway [Member]
Non-Cash Investing And Financing Activities [Line Items]
Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP	0	157
Series A Convertible Preferred stock accrued dividend [Member]
Non-Cash Investing And Financing Activities [Line Items]
Preferred stock dividends	573	509
Series C Preferred stock accrued dividend [Member]
Non-Cash Investing And Financing Activities [Line Items]
Preferred stock dividends	264	103
Series D Preferred Stock [Member]
Non-Cash Investing And Financing Activities [Line Items]
Shares Issued During the Period Connection With Debt Refinancing	2,751	0
Cyalume Specialty Products [Member]
Non-Cash Investing And Financing Activities [Line Items]
Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP	$ 0	$ 241

SUPPLEMENTAL DISCLOSURE OF CA97

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Non-Cash Investing and Financing Activities) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2015shares
Selway Capital, LLC [Member]
Non-Cash Investing And Financing Activities [Line Items]
Stock Issued During Period, Shares, New Issues	242,308
Cyalume Specialty Products [Member]
Non-Cash Investing And Financing Activities [Line Items]
Stock Issued During Period Shares Contingent Consideration Liability	350,000

SUBSEQUENT EVENTS (Additional I

SUBSEQUENT EVENTS (Additional Information) (Details)	Feb. 19, 2016USD ($)
Credit Agrement [Member] | Subsequent Event [Member]
Debt Instrument, Annual Principal Payment	$ 247,000